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MECHANISM OF CANDIDA ALBICANS BIOFILM AND VIRULENCE INHIBITION BY A  
BACTERIAL SECRETED FACTOR 
 
 
Carrie Elaine Graham, M.S. 
 
Advisory Professors: Danielle A. Garsin, Ph.D. and Michael C. Lorenz, Ph.D.  
 
 The human microbiome is a diverse polymicrobial population comprised of both fungi 
and bacteria. Perturbations of the normal microbiome can have a profound impact on health, 
including the development of infections. Exploitation of these polymicrobial interactions has the 
potential to provide novel treatment and prevention strategies for infectious diseases. 
Enterococcus faecalis, a Gram-positive bacterium, and Candida albicans, a polymorphic 
fungus, occupy overlapping niches as ubiquitous constituents of the gastrointestinal and oral 
microbiome. Both species are also amongst the most important and problematic, opportunistic 
nosocomial pathogens and are often co-isolated during infection. Surprisingly, these two 
species antagonize each other’s virulence in both nematode infection and in vitro biofilm 
growth.  
 Herein we identify the E. faecalis secreted bacteriocin, EntV, as both necessary and 
sufficient for the reduction of C. albicans virulence and biofilms through the inhibition of hyphal 
formation, a critical virulence trait of C. albicans. Furthermore, we demonstrate that the EntV 
propeptide is proteolytically processed by the metaloprotease, GelE, in E. faecalis, resulting in 
production of a highly active peptide of 68-amino acids, EntV68. The mature peptide effectively 
blocks biofilm development in multiple media conditions and disrupts pre-formed biofilms, 
which are resistant to current antifungal treatments. Moreover, EntV68 is efficacious against 
clinical strains of C. albicans, including azole resistant strains. Biofilm development of other 
 vii 
pathogenic Candida species is also impeded by EntV68 treatment, demonstrating the target 
spectrum of EntV68 is not limited to C. albicans. EntV68 is protective in the murine macrophage 
and oropharyngeal candidiasis (OPC) infection models at nanomolar concentrations. Epithelial 
invasion, inflammation, and fungal burden in the OPC model were significantly reduced in 
response to treatment with EntV68. Collectively, C. albicans cells present in the hyphal form 
were greatly reduces in all models examined. Despite these profound effects, EntV68 has no 
effect on C. albicans viability, even in the presence of significant host-mimicking stresses. 
EntV68 associates with cell surface of both yeast and hyphal cells of C. albicans and deletion of 
genes involved in hyphal morphogenesis and cell wall composition abrogate the inhibitory 
activity in C. albicans biofilms. These findings demonstrate that EntV has potential as a novel 
antifungal agent that targets virulence rather than viability. 
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CHAPTER 1:  
 
Background and Significance 
  
 15 
C. albicans as an Opportunistic Pathogen 
 Candida spp. rank 3rd among nosocomial pathogens, with C. albicans being the 
prevalent species and there is a 30% rate of morbidly in device-associated infections in the 
U.S. (1-4). There are two-main types of infections caused by C. albicans that differ very 
drastically in severity: superficial infections of the mucosa, such as oral or vaginal candidiasis 
and life-threatening systemic infections that occur when C. albicans enters the blood stream 
and then infects organs throughout the body (5-7). C. albicans has specialized virulence and 
fitness attributes that allow it to survive and adapt in diverse environments in the host (5). The 
transition between yeast and hyphal morphotypes, expression of cell surface adhesins, and 
biofilm development are among these adaptive traits that are also considered important 
virulence factors (6). 
 As a commensal C. albicans can live in equilibrium with the normal bacterial flora on 
mucosal surfaces (3, 4, 8). C. albicans is transmitted at birth from mother to infant and no 
external environmental reservoirs exist, which suggests that C. albicans has coevolved with the 
mammalian host (9) However, these commensal populations are frequently the source of 
infection that arise from transmigration through the mucosal barrier or colonization of implant 
devices (10). Several factors have been identified that influence the switch from commensalism 
to pathogenesis in C. albicans such as: (1) changes in the normal microbial flora, (2) damaged 
epithelial barriers, and (3) immune dysfunction (4, 8, 11). After the onset of C. albicans 
superficial infections more severe systemic infections can occur (11-13). These blood-borne 
disseminated infections often have considerable mortality rates, near 40%. Severe Candida 
infections are most prevalent in immunocompromised individuals, such as those with HIV/AIDS 
or being treated with immunosuppressive therapy (14-17). Healthy individuals with implanted 
medical devices are also commonly plagued with Candida infections that stem from 
colonization of the medical devices (18, 19).  
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Clinical Importance of Biofilms  
 C. albicans has the ability to produce highly structured biofilms on abiotic and biotic 
surfaces, which promotes the high morbidity and mortality correlated with device-associated 
infections (20, 21). These highly structured biofilms are composed of different cell types that 
form a striated pattern with round, budding yeast-form cells and/or oval pseudohyphal cells at 
the bottom and elongated, cylindrical hyphal cells at the top encased in an extracellular matrix 
(Fig. 1.1) (22-25). Of the bloodstream infections in the clinical setting 15% are caused by C. 
albicans or closely related species; however, C. albicans is the predominant fungal species 
found on medical devices (26-28). Different medical devices used throughout the body are 
susceptible to C. albicans biofilm, such as mechanical heart valves, pacemakers, central 
venous and urinary catheters, dentures and joint prosthetics to name a few (2, 29-31) .  
 Biofilms formed on medical devices have the potential to seed disseminated 
bloodstream infections that can lead to systemic infections of tissue and organs. Astonishingly, 
50% of the over five million central venous catheters placed annually in the U.S. become 
infected with biofilms, both bacterial and fungal (2, 32). Routinely, once a medical device 
becomes infected it is removed and the patient will undergo antimicrobial therapy. Since fungal 
biofilms are resistant to traditional antifungal treatments, increased concentrations and longer 
durations of antifungal treatment are required (33-37). However, in some cases removal of the 
infected medical devices is costly or unsafe and the extremely elevated antifungal 
concentrations used to treat the infection can lead to further complications such as kidney or 
liver failure (15, 37, 38). Thus, due to the complicated nature of device-associated infections in 
the U.S. alone, $6.5 billion is spent annually to treat these types of infections (39). Not only do 
these infections have an immense economic impact, but also a significant health impact 
resulting in an estimated 100,000 deaths per year (39).  
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Figure 1.1: Stages of C. albicans biofilm development over time. 
1) Adherence: yeast cell attach to an abiotic or biotic substrate. 2) Initiation: biofilm 
development starts with cell-cell adhesion and hyphal morphogenesis. 3) Maturation: hyphal 
cells form an extensive network encased in a secreted, extracellular matrix. 4) Dispersal: yeast 
cells bud off the biofilm and disperse and adhere at new locations. Modified from: Finkel JS, 
and Mitchell AP. Genetic control of Candida albicans biofilm development. Nature Reviews 
Microbiology; 2010;9:109–18 (40-42). Permission to use this figure was granted by Copyright 
Clearance Center (License #:  4242690280081).  
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Role of Hyphal Morphogenesis During Biofilm Formation 
 Biofilm formation can be divided into four distinct stages composed of different 
populations of yeast, psuedohyphal, and hyphal cells (Fig. 1.1) (23, 39, 40). C. albicans yeast-
hyphal transition is essential for maximum virulence potential and the biofilm growth cycle (13, 
20, 21, 43). The early stages of biofilm formation are adherence and initiation, which consist of 
yeast cell attachment to a substrate followed by development of psuedohyphae and then 
hyphae. During maturation of the biofilms, cells are encased in an extracellular matrix, biomass 
increases, and striated layers of yeast (bottom) and then hyphal cells (top) are observed. The 
final stage of biofilm formation is dispersal where yeast cells bud off and disperse, allowing 
them to form biofilms in other locations (Fig. 1.1) (23, 39, 40). The stages of biofilm growth are 
interdependent with regulation of hyphal morphogenesis and controlled by a complex signaling 
network. 
 Hyphal morphogenesis is regulated by intricate interconnected pathways in response to 
environmental signals that induce or repress hyphal morphogenesis, giving rise to the distinct 
morphologies that have been observed in C. albicans (13). Morphological variability allows C. 
albicans to adapt to different environmental changes. Intriguingly, many of the distinct 
morphologies can be observed during biofilm growth at distinct stages of development, 
indicating differences in gene expression of biofilm cells in response to the biofilm 
microenvironment. To form the striated biofilm structure described above cells must be able to 
regulate hyphal morphogenesis (40, 42, 44, 45).  
 Three major signaling cascades have been identified to date that regulate hyphal 
morphogenesis in C. albicans: (1) the cyclic AMP-protein kinase A pathway (cAMP-PKA), (2) 
mitogen-activated protein kinase pathway (Cph1-MAPK), and (3) pH pathway (Rim101) (46-
48). The cAMP-pKA pathway is the central signaling pathway that responds to an array of 
different conditions and regulates hyphal morphogenesis during biofilm growth via activation of 
Ras1 (GTPase) by an unknown signal and receptor (49) (Fig. 2.1). Upon Ras1 activation, 
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cAMP is synthesized from ATP by adenylyl cyclase (Cyr1) (50, 51). cAMP then activates PKA, 
which  consists of one of two redundant catalytic subunits, Tpk1 and Tpk2, and a regulatory 
subunit, Bcy1. PKA then phosphorylates the downstream transcription factor, Efg1, which 
regulates hyphal-specific genes (52, 53).  
 Efg1 is a key regulator of hyphal morphogenesis and has various functional roles in 
both the repression and the induction of hyphal morphogenesis. This multi-functionality is owed 
impart to the multiple functional domains of the protein (53). Efg1 is able to bind at least two 
different DNA binding motifs (E-box and MCB). It interacts with the terminal transcription factors 
of the other hyphal signaling cascades and modulates their functions. Post-translational 
modifications are also thought to modulate the regulatory behavior of Efg1 (53, 54). Efg1 is one 
of the core master regulators (Flo8, Rfx2, Gal4, Brg1, Bcr1, Rob1, Efg1, Ndt80, and Tec1) that 
positively regulate biofilm development and form an intricately regulated transcriptional network 
that controls biofilm-associated genes (Fig. 1.2) (23, 42, 55). Recently, an even larger set of 
genes has been identified that encompasses this subset of core master regulators to include a 
total of 51 transcription factors that regulate different aspects of biofilm development (56).  
 Additionally, other key transcriptional regulators of interest include the negative 
regulators Nrg1 and Rfg1 that with co-repressor Tup1 negatively regulate hyphal-specific 
genes and allow dispersal of yeast cells in the final stage of biofilm development (57). The 
positive regulator of hyphal-specific genes, Ume6, is important for hyphal extension by 
maintaining expression of hyphal-specific genes and is important for the later stages of biofilm 
growth (54, 57, 58). Downstream from every hyphal morphogenesis signal cascade, Ume6 is 
thought to be a global positive regulator of hyphal-specific genes and is negatively regulated by 
Nrg1-Tup1 and to a lesser extent by Rfg1-Tup1 (59). 
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Figure 1.2: C. albicans hyphal and biofilm development signaling cascade.  
Ras1-cAMP-PKA (purple) is responsible for transducing the environmental signal to the 
terminal transcription factor Efg1 (blue). Activated Efg1 is part of the biofilm core 
regulators and positively regulates the biofilm transcriptional network (green), hyphal 
specific and biofilm-associated genes. The positive regulator Ume6 regulates hyphal 
elongation (brown) and is important for developing mature biofilms. Repressors Nrg1 
and Rfg1 with the co-repressor Tup1 (red) negatively regulate the signaling cascade 
and are important for the late biofilm stage, dispersal. Modified from Sudbery PE. 
 21 
Growth of Candida albicans hyphae. Nature Reviews Microbiology; 2011;9:737-748 . 
Permission to use this figure was granted by Copyright Clearance Center (License #: 
4242730485058). 
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Biofilm-Associated Genes  
 Nobile et al. (42) identified a subset of genes that are differentially regulated during 
biofilm development. This subset of genes is regulated by different combinations of the six-
biofilm master regulators and includes cell wall proteins, metabolic proteins, and transporter 
proteins. Functional analysis of these genes during biofilm growth revealed that cell wall 
proteins play a direct role in biofilm development (42). Considering that the cell wall interacts 
most directly with surface substrates and other cells it is no surprise that the cell wall and 
surface proteins play a major role in biofilm formation. The cell wall of C. albicans is comprised 
of primary carbohydrates and glycoproteins (8, 12). Chitin, β-1,3-glucan, and β-1,6-glucan 
comprise the inner wall just above the cell membrane, while cell wall proteins and mannans 
that are in the form of N- and O-linked glycosylation on the cell wall proteins constitute the 
outer wall (Fig. 1.3) (8, 13). Adhesins directly mediate adherence to a substrate or other cells. 
Several different adhesins have been identified in C. albicans by deletion of the gene resulting 
in loss of adherence or due to homology to known adhesins (60). The content of the cell wall 
and surface proteins can affect adhesin activity that results in masking or exposing adhesins to 
the cell surface (8, 13, 60). 
 Two different classes of cell wall proteins have been identified in C. albicans: proteins 
glycophosphatidylinositol (GPI) anchored to β-1,6-glucan and proteins with internal repeats 
(Pir) linked to β-1,3-glucan (60). The GPI anchored cell wall proteins are the most abundant 
and many are important for biofilm formation. One such protein is hyphal wall protein 1 (Hwp1), 
a well-characterized GPI-anchored cell wall protein that is covalently linked to β-glucan. 
Deletion of hwp1 reduces virulence in a mouse infection model and results in biofilm defects 
(42, 55, 61, 62). The ALS (agglutinin like sequence, Als1-7, 9) family of proteins is a family of 
GPI-anchored cell wall proteins, of which several have been identified as being important for 
biofilm formation. Als1 and Als3 have both been shown to play important roles in hyphal 
 23 
 
Figure 1.3: The Candida albicans cell wall.  
Two distinct layers make up the cell wall. The outer layer composed of O- and N-linked 
mannans covalently linked to proteins to form glycoproteins. The inner layer is comprised of 
polysaccharides β-1,3-glucan, and β-1,6-glucan and chitin. Modified from Gow NA, Hube B. 
Importance of the Candida albicans cell wall during commensalism and infection. Current 
Opinion in Microbiology; 2012;15:406–12 (13). Permission to use this figure was granted by 
Copyright Clearance Center (License #: 4242731391290).  
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morphogenesis and biofilm formation; deletion mutants have defects in biofilm growth (62, 63). 
Over expression of the other ALS genes rescues the in vivo and in vitro biofilm growth defects 
of an als1Δ/Δ als3Δ/Δ mutant, indicating redundancy in the function of the Als family of proteins 
(62).  
 Both HWP1 and ALS1 are regulatory targets of BCR1 and over expression of either 
rescues a bcr1 biofilm defect (42). However, overexpression of HWP1 does not rescue biofilm 
growth defects of an als1Δ/Δ als3Δ/Δ mutant suggesting they have distinct roles during biofilm 
formation (62). When biofilms of mixed mutant strains (als1Δ/Δ als3Δ/Δ and hwp1Δ/Δ) are 
grown together the biofilm defects are overcome indicating Hwp1 and Als1/Als3 have 
complementary functions (62). Heterologous expression of HWP1 in S. cerevisiae mediates 
adherence to wild-type C. albicans but not the als1Δ/Δ als3Δ/Δ mutant (62). Taken together 
these results suggest Hwp1 and Als1/Als3 have distinct complementary roles during biofilm 
growth by mediating cell-cell attachment via interactions together on the cells surface.  
 Additional cell wall associated proteins have been shown to play important roles in 
biofilm formation. Eap1 (enhanced adherence to polystyrene 1) is a GPI anchored protein with 
a similar structure to the Als family and is important for biofilm initial adherence. Deletion of 
eap1 causes a reduction in adherence to polystyrene and causes defects in both in vivo and in 
vitro biofilm growth (64, 65). Rbt1 (repressed by Tup1) is also a GPI anchored protein that 
belongs to the same family of adhesins as Hwp1 (60). Deletion of RBT1 results in mild biofilm 
defects in vitro although additional deletions of HWP1 and HWP2 have enhanced biofilm 
defects (66, 67). Expressed at high concentrations in C. albicans yeast cells, Ywp1 (yeast wall 
protein 1) is an adhesin-like cell wall protein that is thought to act as an anti-adhesin by an 
unknown mechanism (68, 69). Deletion of YWP1 results in loss of dispersal and increased 
adherence suggesting that Ywp1 is important for dispersal, the final stage of biofilm 
development (69). Most of the multiple families of adhesins are associated with hyphal growth 
and play a major role in biofilm development. However, a balance of cell-substrate and cell-cell 
adherence is important for biofilm integrity. Cabral et al. (70) found that overexpression of 
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certain cell wall adhesins, such as PGA22, disrupted biofilm growth. Furthermore, upregulation 
of cell adhesins had different consequences in mono-culture biofilms compared to 
polymicrobial. Thus, regulation of cell ahesions is dependent on the nature of the biofilm and 
substrate.   
 The secreted aspartyl proteases, (Sap1-10), are secreted proteases that are 
differentially expressed in hyphal and yeast cells and important for adhesion, invasion and 
tissue degradation during infection (11, 71). During biofilm formation the SAP-encoding genes 
are significantly upregulated in both in vitro and in vivo growth conditions (42, 71). In denture 
stomatitis, inflammation of the palatal mucosa in denture wearers is induced by biofilm growth 
on the surface of the top of denture. Under these conditions, SAP8 expression is highly 
unregulated followed by SAP5, 6, 2 and 1. Overall a positive correlation between proteinase 
activity and biofilm formation associated with infection have been observed in C. albicans oral 
isolates (71, 72). Bloodstream isolates of C. albicans have upregulated gene expression of 
SAP5 and 9 during in vitro biofilm growth compare to isolates from other sites (73). Deletion of 
SAP5 and 6 causes in vivo and in vitro biofilm defects (74).  
 The Saps have been shown to be hyphae-specific genes important for induction of 
hyphae-infiltration (4, 75). However, the observations during biofilm growth suggest that the 
Saps have functions distinct from hyphal invasion during infection (71-74). Defects in biofilm 
adhesion suggest that these proteases are required for proper adhesion during the initiation 
stage (74). Thus, the Saps may also play a role in both seeding new biofilm after dispersal and 
maintaining adhesion during biofilm maturation (71, 73, 74). The dynamic expression of the 
SAP genes over time suggests they play different roles during the stages of biofilm 
development such as nutrient acquisition, cell-cell interactions (adhesion, quorum sensing), 
and extracellular matrix production and remodeling (42, 71-74, 76).  
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Antifungal treatment strategies 
 Traditional antifungal drug development is limited because humans and fungi are 
evolutionarily closely related resulting in a limited number of probable drug targets and greater 
potential for toxicity due to off target affects (77-79). Currently, three classes of traditional 
antifungals (polyenes, azoles, echinocandins) are commonly used to treat C. albicans 
infections (80). These antifungals have different advantages and limitations with toxicity and 
cross reactivity being the main challenges (78).  
 Polyenes were the first antifungals discovered and are natural derivatives of antifungals 
from Streptomyces spp. (77, 81). Polyenes generate pores in the cell membrane by binding 
ergosterol, leading to ion leakage and ultimately cell death (82, 83). The most successful 
polyene is Amphotericin B and is commonly used for serious fungal infections, but has severe 
toxic side affects (77, 84). Azoles disrupt the cell membrane fluidity by disrupting biosynthesis 
of ergosterol and are extensively used because of their low toxicity (85). Fluconazole, 
itraconazole, voriconazole, and posaconazole are the most commonly used azoles and are 
often used as a first measure against fungal infections (77). Azole resistance has increased 
with the widespread use of azoles in the clinical setting (83). Echinocandins are the newest 
class of antifungal and inhibit cell wall biosynthesis by inhibiting β-1,3-glucan synthase (Fks1) 
(86). Caspofungin, anidulafungin, and micafungin are the most commonly used echinocandidns 
and have little to no side effects (87). 
 
Antifungal Resistance in C. albicans Biofilms 
 The ability of C. albicans to form biofilms influences antifungal drug resistance due, in 
part, to the inability to disrupt or permeabilize the biofilms (88, 89). The inability to disrupt C. 
albicans biofilms correlates with the hypha-yeast ratio, where biofilms with more than 50% 
hyphae have a significant increase in compression strength thus increasing resistance to 
disruption (90). Therefore, the structure of the biofilm allows C. albicans to persist even in the 
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presence of antifungals (20, 21, 88). Biofilms of C. albicans are up to 1,000-fold more resistant 
to antifungals compared to planktonic cells (20, 88, 91, 92).  
 One key characteristic of biofilm growth is the encasement of the biofilm in the 
protective extracellular matrix that protects the biofilm integrity and acts as a physical barrier 
against antifungal agents. The extracellular matrix of C. albicans biofilms is comprised of 
proteins, polysaccharides, lipids, and nucleic acid. Although each of the extracellular matrix 
components augment the architecture and integrity of the biofilm, only polysaccharides and 
nucleic acid have been shown to enhance antifungal resistance (93-97).   
 The extracellular matrix also contains polysaccharides, mostly mannan-glucan 
complexes (98). The β-1,3-glucan synthase gene, FKS1, produces cell wall β-1,3-glucan that is 
deposited into the ECM of C. albicans biofilms. Nett et al. (20, 99) demonstrated that β-1,3-
glucan sequesters antifungals, impeding diffusion of the antifungal and conferring resistance of 
the biofilm to antifungals. Heterozygous deletion of FKS1 (GSC1) reduced β-1,3-glucan 
synthesis and deposition in the extracellular matrix, which increased biofilm susceptibility to 
fluconazole (99). Moreover, depletion of β-1,3-glucan by β-1,3-glucanase treatment increased 
sensitivity to fluconazole. Whereas, addition of exogenous β-1,3-glucans increases resistance 
to fluconazole in planktonic cells (20).  
 Another component of the extracellular matrix that contributes to antifungal resistance is 
extracellular DNA (eDNA). DNase treatment enhances caspofungin and amphotericin B 
disruptive activity of mature biofilms (100). eDNA contributes to the maintenance and stability 
of biofilms and is not required for the early biofilm stages (adherence and initiation). DNase 
treatment of mature biofilms disrupts biofilm integrity, but does not affect establishment of 
biofilm (101). Moreover, addition of eDNA to biofilms increases biofilm biomass and does not 
affect adherence (101). eDNA is also present, to a lesser extent, in the supernatant of 
planktonic cells and can be enhanced by addition of chitinase in both planktonic and biofilm 
cells suggesting that the eDNA source is from cell lysis (97, 100, 101).   
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 Efflux pumps also contribute to the intrinsic resistance of C. albicans biofilms. There are 
two major classes of efflux pumps in C. albicans: ATP-binding cassette transporters (CDR1 
and CDR2) and major facilitator class pumps (MDR1) (80, 102, 103). In the presence of 
antifungal drugs these efflux pumps are upregulated in planktonic cells (80, 102). However, 
during biofilm growth these efflux pumps are upregulated in response to surface adherence, 
which further influences resistance to antifungal agents (42, 104, 105). Independent of efflux 
pumps, persister cells contribute to antifungal resistance in biofilms (88). Biofilms are 
metabolically heterogeneous, with cells at the base more dormant than those at the surface. 
Persister cells are metabolically dormant yeast cells found in biofilms of C. albicans that are 
exceedingly resistant to antifungals and can survive very high concentrations of antifungal 
drugs to seed new biofilms once antifungal treatment ceases (88, 106). Most antifungal are 
fungistatic and not fungicidal and are more effective against actively growing cells, which 
explains the resistance observed in persister cells. 
 Due to the rise in antifungal resistance the discovery of novel antimicrobial agents is 
imperative. The rise in resistance to traditional antimicrobials is due impart to targeting 
essential processes that increase the selective pressure for mutations that confer resistance (3, 
91, 92). One promising alternative is the use of antimicrobials that target virulence factors, such 
as hyphal morphogenesis and the biofilm matrix in C. albicans (3, 4, 92). Although immense 
advances have been made recently in understanding the molecular details of hyphal 
morphogenesis and biofilm formation, clinical application of virulence targeting therapeutics has 
remained underexplored.  
 
Bacterial and C. albicans Interactions and Health Related Prevalence 
 In the host C. albicans encounters hostile environments with antagonism from the host 
and commensal bacterial flora. As a result C. albicans has developed a multitude of strategies 
to overcome these challenges, making C. albicans a resilient pathogen (107). However, in a 
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healthy host C. albicans is for the most part benign. Although the switch from commensal to 
pathogen is largely dependent on the status of the host, the microflora and presence of other 
pathogens also play a role in this switch. As both a commensal and pathogen of the human 
host C. albicans encounters numerous bacterial species, which include both pathogenic and 
commensal species (11, 108-111).  Complex interactions have been previously documented 
that include both synergistic and antagonist interactions where bacteria and C. albicans can 
have direct or indirect interactions (108, 110). These interactions can influence the growth and 
physiology of both microbes, often modulating the virulence of C. albicans (108, 112, 113). 
Physical interactions where bacteria adhere to C. albicans has been demonstrated with specific 
affinity for hyphal cell wall adhesins (112-114). Chemical exchange between C. albicans and 
bacteria that involves crosstalk between quorum sensing molecules has also been 
demonstrated in previous studies (114, 115). 
 Apart from the studies described here, there are only three bacterial species whose 
interactions with C. albicans have been significantly characterized, Pseudomonas aeruginosa, 
Staphylococcus aureus, and Streptococcus gordonii. As the complexity of these types of 
interactions are being uncovered, two main types of interactions have been observed: 
antagonism between pathogens (P. aeruginosa−C. albicans) and synergism between 
pathogens (S. aureus−C. albicans, S. gordonii−C. albicans) (110, 113, 116). 
Antagonistic Interactions 
 Antagonistic interactions between P. aeruginosa and C. albicans have been the most 
extensively examined and reveal a complex dynamic between two pathogens that are 
commonly co-isolated from the lungs of cystic fibrosis (CF) patients (117-119). A Gram-
negative bacterium, P. aeruginosa is an opportunistic pathogen with a multitude of virulence 
factors (120). In clinical cases where C. albicans is found during pulmonary infection, such as 
pneumonia and cystic fibrosis-related infections, it is usually co-isolated with bacteria (121, 
122). Furthermore, C. albicans and P. aeruginosa are commonly co-isolated from burn wounds. 
Burn victims often have primary infections of P. aeruginosa that are followed by severe life-
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threatening candidemia (108). Similarly, increased virulence was observed in a murine 
pseudomonal burn wound infection model during co-infection with P. aeruginosa (123). In vitro 
investigations in rats found that pre-colonization with C. albicans in lung tissue increased rates 
of P. aeruginosa associated pneumonia (122). This suggests that C. albicans mucosal biofilms 
promotes secondary bacterial infections, which has also been supported by a clinical study of 
ventilator patients who had an increased rate of bacterial infection with prior C. albicans 
colonization (124). 
  Conversely, in vitro examination of C. albicans and P. aeruginosa demonstrated 
antagonistic interaction in a wide range of environmental conditions. During biofilm growth P. 
aeruginosa preferentially adheres to C. albicans hyphal cell and forms biofilms on the hyphae, 
which leads to killing of C. albicans. This hyphal specific killing is due to the production of 
pseudomonal virulence factors, secreted haemolytic phospholipase and phenazines (125-127). 
Furthermore, P. aeruginosa inhibits the yeast-hyphal transition by production of a 3-oxo-C12 
homoserine lactone, a bacterial quorum sensing signaling molecule that mimics farnesol (126, 
128). Farnesol is a quorum sensing signal molecule produced by C. albicans, which represses 
hyphal morphogenesis and plays an important role during biofilm dispersal (40, 129). Farnesol 
and 3-oxo-C12 homoserine lactone inactivate the Ras1-cAMP-PKA pathway and increase 
TUP1 expression, thus blocking expression of hyphal-specific and biofilm genes that are 
positively regulated by Efg1 (129-133). Homoserine lactones and similar compounds are 
produced by other Gram-positive bacteria that similarly repress hyphal morphogenesis in C. 
albicans, suggesting cross-talk between bacteria and C. albicans might be important in 
polymicrobial interactions (134, 135).  
 In addition to the effects P. aeruginosa has on C. albicans, C. albicans does exert 
changes in P. aeruginosa. Farnesol inhibits the Pseudomonas quinolone signal (PQS), which 
responds to the production of 3-oxo-C12 homoserine lactone in P. aeruginosa and controls the 
production of phenezine products (136). During co-culture of P. aeruginosa and C. albicans, a 
reduction in PQS and thus phenezine products, suggests that the production of farnesol from 
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C. albicans is great enough to have an influence on P. aeruginosa (136). Taken together these 
results suggest an antagonistic relationship exists. However, these pathogens are frequently 
found during co-isolation in the clinical setting suggesting that a synergistic relationship might 
exist in certain settings. It is possible that the antagonistic behaviors observed in vitro allow P. 
aeruginosa to use C. albicans biofilms as a sort of scaffold or foundation, thus increasing the 
survival and colonization rates. There is apparent antagonism in vitro, but synergism in vivo, 
similar to our observation with E. faecalis and C. albicans.  
 Antagonist interactions between C. albicans and Streptococcus mutans have also been 
documented. S. mutans are Gram-positive bacteria found in the oral cavity and are associated 
with dental caries. They are resistant to highly acidic environments and produce acids that are 
associated with dissolution of the tooth surface, which leads to dental caries (137, 138). S. 
mutans and C. albicans are commonly co-isolated from early childhood dental caries and 
denture plaques of healthy individuals (139, 140). Similar to P. aeruginosa, S. mutans produces 
quorum sensing signaling molecules that inhibit C. albicans hyphae development.   
 The competence-stimulating peptide (CSP) was found to inhibit hyphal development in 
C. albicans (141). CSP is necessary for natural competence of S. mutans. Additionally, trans-2-
decenoic acid, a diffusible signaling molecule inhibits hyphal development of C. albicans (142). 
SigX, an alternative sigma factor in S. mutans, is the master regulator of quorum sensing (143). 
Strong induction of sigX is observed in S. mutans biofilms grown with C. albicans compared to 
monoculture biofilms suggesting that C. albicans stimulates quorum sensing signaling in S. 
mutans (144).   
Synergistic Interactions 
 Adhesion is an important factor for C. albicans colonization, pathogenesis and 
polymicrobial interactions. The ALS proteins in particular play an important role in the biofilm 
lifecycle and polymicrobial interactions. Many of the clinical conditions where C. albicans is co-
isolated with bacteria are considered biofilm-associated and adherence and/or colonization to a 
surface are a requirement for infection (145). The ALS (agglutinin-like sequence) genes encode 
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eight different glycoproteins that contain an N-terminal domain with adhesive function that are 
found diffusely over the cell surface of C. albicans (146).   
 A vital component in inter-kingdom interactions, coaggregation is essential for 
polymicrobial communities found in the oral cavity and facilitates the complex architecture 
found in dental plaques. C. albicans is capable of adhering to various oral streptococcus 
species (S. mutans, S. salivarius and S. gordonii). The ALS proteins mediate these interactions 
with streptococci during polymicrobial biofilm development. Specifically, Als3 in C. albicans is 
necessary for biofilm formation with S. gordonii on a salivary pellicle (147). Furthermore, S. 
gordonii was able to bind Saccharomyces cerevisiae heterologously expressing C. albicans 
Als3p (147). Als1 was also found to bind to the surface of S. gordonii; the Als proteins have 
similar structures, and thus redundant function is feasible. The presence of S. gordonii 
enhanced hyphal morphogenesis and biofilm formation in human saliva mediated by SspA and 
SspB bacterial surface proteins that interact with Als1 and Als3 (146, 148). Additionally, 
quorum sensing signaling via luxS regulation of autoinducer-2 (A-II) is necessary for enhanced 
hyphal morphogenesis and biofilm formation (149). 
 Synergistic interactions between Staphylococcus aureus and C. albicans have been 
observed. S. aureus has an affinity for binding to hyphal cells of C. albicans that is mediated by 
Als3 on the surface of C. albicans (113). S. aureus, a Gram-positive opportunistic pathogen 
found commonly on the skin, possesses a series of virulence factors that contribute to its 
significant prevalence in nosocomial infections in immunocompromised individuals (150). S. 
aureus was unable to bind to the adhesin-deficient mutant strains of C. albicans ALS3 (113). In 
addition, S. aureus was able to bind the recombinant purified N-terminal domain of Als3 and 
Saccharomyces cerevisiae heterologously expressing C. albicans Als3p (113). In an ex vivo 
murine co-infection model, tongues excised from mice where inoculated with C. albicans and S. 
aureus in a 12-well plate, S. aureus was found in the outer layers of the tissue when tongues 
were infected with S. aureus only or with the ALS3 mutant strain. Conversely, tongues infected 
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with S. aureus and wild-type C. albicans had S. aureus in epithelial tissue with invasive hyphae 
(113). 
 The interactions between C. albicans and S. aureus have also been examined 
extensively in multiple animal models that demonstrate a significant increase in virulence of 
both microorganisms. During intraperitoneal infections of mice with C. albicans and S. aureus, 
mice have increased mortality rates and both microorganisms are found together in the spleen, 
pancreas, and esophagus. This demonstrates synergistic behavior during dissemination from 
the intraperitoneal site of infection, similar to in vitro observations (151-153). Co-infection with 
C. albicans and S. aureus in a peritonitis murine model significantly increased mortality 
compared to mono-infection and increased fungal and bacterial burden was observed during 
co-infection. Increased proinflammatory cytokines (IL-6 and G-CSF) and neutrophil infiltration 
was observed during co-infection. Treatment with nonsteroidal anti-inflammatory drugs 
(NSAIDs) increased mouse survival and lowered fungal and bacterial burdens in the kidneys 
and spleen (154).  
 C. albicans has complex interactions with both pathogens and commensal bacteria 
found in the human host in various niches. These complex interactions can be physical 
interactions where bacteria adhere with specific affinity to hyphal cells, as has been 
demonstrated to occur with C. albicans hyphal cell wall ahesions (112, 113). Chemical 
exchange between C. albicans and bacteria that involves crosstalk between quorum sensing 
molecules has also been observed (133, 155). Furthermore, a combination of these types of 
interactions can transpire between C. albicans and bacterial species, alluding to the complexity 
of the inter-kingdom interactions that occur. 
 
Co-isolation of C. albicans and E. faecalis 
 The most well studied niches of C. albicans are the gastrointestinal (GI) and urogenital 
tracts and it is well documented to come into contact with the bacterial flora, such as 
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Enterococcus faecalis. Interestingly, co-isolation of C. albicans and E. faecalis is common, of 
which the frequency is likely due to their biological similarities, specifically colonization of 
overlapping niches (156-158). Both are opportunistic pathogens causing serious infection in the 
presence of immunological dysfunction. 
 The prevalence of C. albicans and E. faecalis co-isolation from sites throughout the 
human host is effectively demonstrated by a large-scale retrospective examination of 67,765 
different clinical samples (109). The samples were collected at a large teaching hospital in 
Germany over a two-year period. Candida spp. were detectable in about 7.7% of the samples 
that included blood, CSF, feces, sputum and skin. The frequency of E. faecalis isolation 
increased 2-fold in the Candida-positive samples compared to Candida-negative samples. This 
trend was further increased in Candida-positive samples from blood and ICU patients, 
demonstrating the prominence of co-infection in more severe infections and individuals with 
pre-existing medical conditions (109). 
 Commonly co-isolated from the oral cavity of individuals with secondary root canal 
infections, C. albicans and E. faecalis are typically resistant to antimicrobials, a probable cause 
for failed root canal treatment strategies (159). During root canal treatment, the infected root 
canals are mechanically removed and irritants are chemically removed followed by blocking the 
root canal system with dental filling (gold, porcelain, silver amalgam, polymethyl methacrylate 
resin, PMMA) to eliminate microbial activity thus preventing reinfection. However, absolute 
removal of all microorganisms from the root canal is not always achieved and the oral cavity is 
abundant with microorganisms that can colonize microspaces between the dental filling acrylic 
and tooth surface (160-162).   
 Multifaceted microbial communities that consist of anaerobic bacteria (strict and 
facultative) and fungi reside in the root canals of infected teeth (163, 164). Of these microbes, 
E. faecalis and C. albicans are equipped to resist various endodontic treatment strategies that 
allow them to survive and cause secondary root canal infections. (165-167). 
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 Many studies demonstrate the importance of C. albicans and E. faecalis separately 
during secondary root canal infection. Yet, only a handful of studies investigate the co-isolation 
of these microorganisms. Given their pathological similarities during periodontal infections it is 
plausible that the occurrence of co-infection rates is underrepresented. A study investigating 
single-rooted teeth with pulp necrosis, found that samples collected after root canal treatment 
had increased populations of enterococci co-isolated with Candida spp. and/or enteric bacteria 
(168). However, the majority of samples tested had enterococci mono-infections, suggesting 
that interactions with other microorganisms are not necessary for this type of periodontal 
infection (168). 
 Although secondary root canal infections are treatable with additional surgical removal 
and debridement of the infected root canal and filling, if left untreated can become a more 
severe systemic infection. C. albicans and E. faecalis that survive the root canal system can 
spread to the periodontal tissues and invade the bloodstream, which can lead to bloodstream 
infections (BSI) and followed by development of endocarditis. BSIs with at least two different 
microorganisms are considered polymicrobial BSI and are on the rise with rates ranging from 
5% to 32% of all BSI reports (169-172). With increased mortality rates (21%-63%) compared to 
mono-microbial mortality rates, polymicrobial BSIs are a growing concern (169, 170). 
  Of more than 8000 reported incidences of candidemia (from 1965 to 2007) 23% were 
polymicrobial, suggesting that high rates of polymicrobial BSI occur with candidemia (157). An 
extensive study examining patients with candidemia found that of 372 patients, 141 patients 
from 8 Veterans Affairs hospitals and 231 patients from a tertiary care hospital, 27% had 
polymicrobial BSI (24% with synchronous bacteremia and 3% with more than one Candida 
spp.) (157). Of the patients with synchronous bacteremia (88 patients) 27% where infected with 
Enterococcus spp. Furthermore, the most frequent source of polymicrobial BSI is from intra-
abdominal infections that are frequently the result of loss of GI integrity allowing 
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microorganisms, such as C. albicans and E. faecalis, from the GI tract to infect the peritoneal 
cavity (170, 173-175). 
 Most populations of C. albicans and E. faecalis are located in the GI tract where they 
act as commensals and are for the most part benign. However, if the host becomes 
immunocompromised these microbes can become pathogenic and the populations in the GI 
tract are a common reservoir for more severe types of infections. Intra-abdominal infections 
(IAI) are commonly caused by infection from the GI tract microbiota and include many 
pathological conditions that can range from uncomplicated, where only one organ is infected 
and the infection does not progress to the peritoneum, to complicated, where the infection 
progresses past the organ to the peritoneum causing localized or diffuse peritonitis (176, 
177).   
 Peritonitis is further classified into primary, secondary or tertiary peritonitis (176). 
Primary peritonitis is a disseminated infection with no loss of GI tract integrity and mainly 
occurs in pediatric patients. The most common form, secondary peritonitis is an acute 
peritoneal infection that results from loss of GI integrity due to perforation of the GI tract or from 
intra-abdominal viscera from infected organs (e.g. gangrenous appendicitis). Recurrent 
infections of the peritoneal cavity that follow primary or secondary peritonitis are classified as 
tertiary infections. These types of infections can be acquired from the community or healthcare 
setting. The latter is associated with increased mortality due to the status of the host and multi 
drug resistance of the infections (178). Additionally, increased mortality rates (~%30) are 
associated with severe sepsis or toxic shock in secondary infections (179-181). 
 A retrospective study of 163 adult patients with intra-abdominal candidiasis (IAC) 
compared to 161 patients with candidemia found increased rates of bacterial co-infections in 
patients with IAC (67%) compared to polymicrobial BSI (6%) (182). Different types of IAC were 
evaluated: intra-abdominal abscesses (55%), secondary peritonitis (33%), primary peritonitis 
(5%), infected pancreatic necrosis (5%), and cholecystitis/cholangitis (3%). The most common 
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Candida spp. isolated were C. albicans (56%) and C. glabrata (24%). Consistent with previous 
studies, enteric pathogens (Enterococcus and Enterobacteriaceae) were co-isolated with 
Candida spp (183, 184). Of the 110 patients with bacterial co-infection, enterococci were most 
abundant (29%), followed by Escherichia coli (19%) and Klebsiella spp. (15%) (182). However, 
the mortality rates for IAC mono-infection and IAC bacterial co-infections are comparable in 
these investigations, suggesting that Candida spp. are capable pathogens and not significantly 
modulated by co-infecting bacteria in IAI (182, 185).  
 
E. faecalis Pathogenesis 
 Enterococci are the initial colonizers of the GI tract in infants and were once only 
considered as commensal colonizers with nominal clinical relevance. However, over the last 
four decades, with increased use of antibiotics, enterococci have become prominent 
opportunistic pathogens responsible for causing numerous types of infections: urinary tract 
infections (UTI), IAI, bacteremia, and endocarditis (186). Antibiotic resistance is directly related 
to the emergence of enterococci as a clinically important pathogen and the most clinically 
significant species are Enterococcus faecalis and Enterococcus faecium (186, 187). Since 
enterococci are intrinsically resistant to many antibiotics, have the ability to acquire resistance 
genes, and are tolerant to antibiotics that target the cell wall, treatment of enterococcal 
infections is often problematic (187, 188). Thus, the use of combinational therapy is required to 
synergistically acquire bactericidal effects (189).  
 As part of the microflora enterococci colonize the GI tract of mammals (including 
humans) and insects. Although both E. faecalis and E. faecium colonize humans, E. faecalis 
colonizes the GI tract at a higher density (107 CFU/μg) than E. faecium [191]. E. faecalis is also 
the predominant species of enterococci found in the urogenital tract. The endogenous 
microflora was previously thought to be the predominant source of enterococcal infections. 
Nevertheless with increased investigations in the clinical setting, transmission of pathogenic 
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enterococci from nosocomial sources (e.g. hands of healthcare provider) has been extensively 
documented (190, 191). The ability of enterococci to persist for extended periods on hands (60 
minutes) and inanimate objects (4 months) creates a reservoir for continual transmission in the 
hospital setting (192). Necessary for the numerous types of infections they cause, E. faecalis 
has a multitude of virulence factors, such as: cytolysin, gelatinase, serine protease, 
aggregation substances, Esp (enterococcal surface protein), Ace (adhesin to collagen of E. 
faecalis), EfaA (E. faecalis antigen A), EbpABC (endocarditis and biofilm-associated pili), and 
enterococcal capsule (193). Acquisition of extrachromosomal elements plays an important role 
in adaptation and survival of enterococci (194). Extrachromosomal elements are usually 
acquired by conjugation, where conjugative plasmids are transferred from a donor to recipient 
controlled by peptide sex pheromones (194). Antibiotic resistance, elevated resistance to UV 
light, virulence factors and bacteriocins are frequently plasmid-determined traits. Thus, 
significant genetic diversity in response to environmental selection pressure is observed in 
enterococci (195, 196).  
 Part of the core genome, the proteases, gelatinase (GelE, a matrix metalloprotease) 
and a serine protease (SprE), in E. faecalis are important for degradation and damage of host 
tissues during infection (197). These proteases affect a broad range of host functions by 
degradation of host connective tissues and proteins, and interference with host cell signaling 
and immune response (198, 199). Included in a single operon, GelE and SprE gene expression 
is regulated by the fsr (E. faecalis regulator) genes that encode a canonical two-component 
system, a homolog to the agr (accessory gene regulator) operon in S. aureus (200, 201). 
 The response regulator (FsrA) positively regulates the fsr genes (fsrABCD) and 
downstream virulence factors (gelE, sprE). A quorum sensing two-component system, Fsr 
responds to increased concentrations of a peptide pheromone encoded by fsrD, gelatinase 
biosynthesis-activating pheromone (GBAP) that is secreted and processed by the 
transmembrane protein FsrB.  FsrA is constitutively expressed at basal levels, when threshold 
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concentrations of extracellular GABP have accumulated the histidine kinase, FsrC is 
phosphorylated followed by phosphorylation of the response regulator, FsrA. This signal 
transduction via the Fsr system results in upregulated expression of the fsr genes and 
downstream virulence factors, gelE, sprE (197, 202).  
 Although both GelE and SprE, to a lesser extent, are important virulence factors, only 
GelE activity and role in virulence has been extensively examined. The gelE gene encodes a 
509-amino acid protein of which 29-amino acids at the N-terminus serve as a Sec secretion 
signal sequence. This signal sequence is cleaved upon secretion resulting in release of the 
proenzyme of 480-amino acids. After secretion the proenzyme is further proteolytically 
processed at the N-terminus and C-terminus by an autocatalytic process resulting in the mature 
protein of 33kDa (203, 204).  
 GelE is a member of the M4 family of proteases and is similar to thermolysin from 
Bacillus thermoproteolyticus and aureolysin from Staphylococcus aureus (205, 206). With 
broad substrate specificity, GelE has the ability to hydrolyze gelatin, cleave enterococcal 
conjugative sex pheromones, and has several host-derived substrates important during 
infection (insulin B chain, endothelin, hemoglobin, fibrinogen, fibronectin, collagen, and laminin) 
(207, 208). Furthermore, GelE interferes with the innate immune response by inactivating 
human antimicrobial peptides LL-37 and β-defensins and is pertinent for E. faecalis 
dissemination (209-211). 
 A serine glutamyl endopeptidase of 25kDa in size, SprE is similar to staphylococcal 
glutamyl endopeptidases V8 and GluSE (212, 213). Similar to GelE, insulin, fibrinogen, and 
casein have been observed as substrates of SprE and disruption of sprE results in decreased 
virulence in different infection models, mouse peritonitis, Caenorhabditis elegans, and a rabbit 
endophthalmitis (201, 214-217). SprE enzymatic activity is modified in the presence of GelE 
similar to reports in S. aureus, where the GelE homolog, aureolysin, inhibits autocatalytic 
processing of the SprE homolog, SspA (V8), by proteolytically processing the N-terminus of 
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SspA by aureolysin (218, 219). Purification of SprE proenzyme from gelE mutant supernatant 
resulted in purification of several forms of SprE that were proteolytically processed at both the 
N-terminus and C-terminus (218, 220).  Three different mature forms of SprE were purified that 
had enzymatic activity (Leu1-Ala237, Ser-1-Glu227, Leu1-Glu227). However, only one form of SprE 
(25kDa) was purified from wild-type supernatant (218, 220). Although GelE processes SprE, 
the reverse is not apparent because a sprE insertion mutant produces gelatinase (201). 
 Considering the interconnected gene regulation and proteolytic processing of GelE and 
SprE, it no surprise that they function in combination. While GelE and SprE play independent 
roles in different infection models (mouse peritonitis, Caenorhabditis elegans, rabbit 
endophthalmitis) disruption of both proteases had an additive effect (201, 214-217). Moreover, 
roles for both GelE and SprE have been observed in biofilm development and regulating 
autolysis in E. faecalis (221). Deletion of gelE resulted in a significant reduction in biofilm 
biomass compared to wild-type biofilms. Whereas deletion of sprE resulted in accelerated 
biofilm development and increased autolysis, suggesting that interplay between these 
proteases controls biofilm development in E. faecalis (221). 
 
E. faecalis Commensalism  
 Enterococci colonize the GI tracts of mammals, reptiles, birds and insects, which 
suggests that enterococci have been part of the GI microflora since the early Devonian period, 
(~412 MYA), making them one of the earliest colonizers of the GI tract (222-224). In the human 
GI tract, enterococci are predominantly located in the small and large intestine (jejunal, ileal, 
cecal, and recto-sigmoidal sections) (225). E. faecalis and E. faecium are the predominant 
enterococci found in human feces, and E. faecalis is most common species found in the GI 
tracts of mammals and insects (226, 227).  
 E. faecalis is a member of the lactic acid group of bacteria (LAB), which are low-GC 
gram-positive bacteria that produce lactic acid as a major end product of carbohydrate 
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fermentation [232,233]. Many of the LAB are used as probiotics, specifically Lactobacilli spp., 
which have been shown to benefit GI health (228, 229). In spite of the fact that enterococci are 
as abundant in the human GI tract as lactobacilli, they are commonly associated with being a 
multidrug resistant (MDR) pathogen (228). Although commensal enterococci can act as 
opportunistic pathogens by translocating across the mucosal barrier causing systemic 
infections in immune-compromised individuals, more commonly infections stem from 
colonization, overgrowth, and translocation of hospital-adapted strains that have enhanced 
pathogenicity and antibiotic-resistance (230, 231). 
 Enterococci are commonly used in food fermentation and preservation, traditionally 
used in cheeses, fermented meats and vegetables manufactured in Mediterranean countries 
(232-234). E. faecium and E. faecalis are the most commonly used and impact the ripening and 
aroma development in these food products (229, 233). Enterococci are not purposely added as 
starter cultures to these types of food. However, they occur in high numbers and their natural 
habitat is probably not fermented food, but an outside environmental source that has yet to be 
identified (235).  
 Enterococci as probiotics are used in countries (European Union) other than the US 
(229, 236, 237). E. faecium and E. faecalis are the species most commonly used as probiotics. 
The E. faecium strain SF68 probiotic, was demonstrated to be clinically effective in children for 
treatment of diarrhea and prevention of diarrhea due to antibiotic treatment (238). The efficacy 
of E. faecium SF68 in treatment of intestinal infections is likely due to the strain being part of 
the natural intestinal microflora and having a short doubling time in optimal conditions. Growth 
inhibition of E. coli, Salmonella serovars, Shigella spp. and Enterobacter spp by E. faecium 
SF68 was demonstrated in vitro and shown to tolerate the extreme conditions of the GI tract 
(239). Other probiotic preparations containing E. faecium have been shown to reduce irritable 
bowel syndrome, dysbiosis as a result of foodborne pathogens, and lowering of serum 
cholesterol (240, 241). 
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Bacteriocins Produced by Gram-positive Bacteria 
 Bacteriocins are produced by Gram-positive and Gram-negative bacteria and are 
ribosomally synthesized proteinaceous secreted compounds that have antimicrobial activity 
against other bacteria, typically those that are closely related to the bacteriocin producing 
species. Production of bacteriocins in Gram-positive bacteria, especially the lactic acid bacteria 
(LAB), has been increasingly studied with the growing interest of probiotic LAB. Bacteriocins 
produced by Gram-positive bacteria can be organized into four major groups: (1) lantibiotics, 
(2) small non-modified peptides, (3) large proteins, and (4) cyclic peptides. The classification of 
bacteriocins from Gram-positive bacteria is continually modified with the discovery of new types 
of bacteriocins. However, Heng et. al. (242) have formulated a systematic classification plan 
based on previous literature that encompasses recently characterized bacteriocins (243-245). 
 Class I bacteriocins are the lantibiotic bacteriocins that contain modified amino acids 
that are not genetically encoded   (246). Lantibiotics are produced ribosomally as precursor 
peptides that undergo post-translational modifications to produce the non-genetically encoded 
amino acids lanthionine (Lan), 3-methyllanthionine (MeLan), dehydroalanine (Dha), and 
dehydrobutyrine (Dhb) (247). Class II bacteriocins are small (<10 kDa), unmodified (non-
lantibiotic and non-cyclic) peptides that encompass bacteriocins from diverse origins making it 
the largest class of characterized bacteriocins (248). Although most characterized bacteriocins 
from Gram-positive bacteria are small (<10 kDa), class III contains larger (>10 kDa) 
bacteriocins that are typically heat liable, but not always (243, 249). The most distinctive 
bacteriocins produced by Gram-positive are the cyclic bacteriocins of class IV, which are post-
translationally modified to produce the mature cyclic peptide (250). 
 
Bacteriocin Production in E. faecalis 
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 Enterococci that produce bacteriocins have been isolated form a wide-range of 
environments. Bacteriocin-producing enterococci are commonly found in cheeses, fermented 
vegetables and meats, thus, have been implicated in food preservation (229, 233, 250). The 
high frequency of bacteriocin-producing enterococci isolated from healthy individuals stool 
samples suggests that they are important part of the healthy microflora and may benefit the 
host and microbe (251). Although bacteriocin production in LAB is commonly associated with 
probiotics and benefiting the health of the GI tract, enterococcal bacteriocins have also been 
associated with infection (252, 253). 
 In E. faecalis bacteriocin encoding genes are often carried on mobile genetic elements, 
such as conjugative plasmids, suggesting that efficient dissemination of bacteriocin-producing 
traits may be important for survival and virulence. Cytolysin is a secreted lantibiotic class of 
bacteriocins with cytotoxic effects on prokaryotic and eukaryotic cells (252, 253). 
Epidemiological data support a role for the cytolysin as a toxin in human infection. Enrichment 
for cytolysin expressing E. faecalis has been observed in the hospital-acquired populations 
compared to community acquired populations of isolates derived from infection (254). These 
findings suggest that selection pressure for cytolysin activity is prevalent in the hospital 
environment, which corresponds to experimental and clinical evidence that cytolysin activity 
plays an important role during infection (255). 
 On the other hand, the heat-stable circular bacteriocin AS-48 produced by E. faecalis 
strains that are commonly isolated from cheese, milk, and fermented food products has 
potential as food biopreservative (250, 256). This bacteriocin is encoded on a plasmid that 
contains ten biosynthetic genes (257). Arranged into five alpha helices giving it a compact 
globular structure, this 70 amino acids bacteriocin is circularized head to tail by a peptide bond. 
AS-48 has broad inhibitory spectrum that includes both Gram-positive and Gram-negative 
species (250). AS-48 is active against foodborne pathogens, toxigenic bacteria and bacteria 
associated with food spoilage (258).  
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 The role of bacteriocins production in natural environments is debatable. However, one 
logical and common idea is that bacteriocins provide the producing organism with a fitness 
benefit that allows them an ecological advantage over competitors (259). The occurrence of 
bacteriocins as a beneficial probiotic trait in the human GI tract and as a virulence trait during 
infection, suggests that bacteriocin production allows enterococci the ability to adapt to different 
environmental conditions. Moreover, bacteriocins enriched during infection associated with 
antibiotic resistance are different from bacteriocins associated with commensal enterococci 
from healthy individuals (260).   
 
Bacteriocins as Treatment Strategies 
 Bacteriocins produced by LAB have mainly been used and extensively studied in 
biopreservation. However, more recently the interest for using bacteriocins for biomedical 
applications has increased with investigations for the use of bacteriocins against pathogenic 
microorganisms still gaining significance (261). Studies examining biomedical application of 
LAB bacteriocins include efficacy analyses against systemic infections caused by S. aureus 
and P. aeruginosa, oral infections caused by Streptococci, and vaginal infections caused by 
Gardnerella vaginalis (262, 263). 
   One of the most extensively characterized bacteriocins is the lantibiotic nisin that is 
produced by LAB (Lactococci and Streptococci) (264, 265). First characterized in Lactococcus 
lactis isolated from fermented milk cultures, nisin is approved by the Joint Food and Agriculture 
Organization/ World Health Organization (FAO/WHO) and the Food and Drug Administration 
(FDA) for use as biopreservative (244, 265). Nisin A from Lactococcus lactis is a small (34 
amino acids) cationic peptide that contains five lanthionine rings that are formed by dehydration 
of precursor serines and threonines that react with neighboring cysteines to give lanthionine or 
3-methyllanthionine that contain a thioether group (266).  
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 Nisin A targets lipid II, which is essential for bacterial cell wall biosynthesis and growth, 
(267, 268). The high affinity for binding lipid II initiates pore formation in the membrane leading 
to depletion of the membrane potential due to leakage of cellular content followed by cell death. 
Nisin A has broad spectrum of activity against Gram-positive bacterial pathogens (foodborne 
and non-food related) and Gram-negative bacteria when used in conjunction with antibiotics 
(269, 270). Other natural variants of nisin have been identified from different Lactococcus spp. 
and Streptococcus spp (270). Although, these natural variant share similar structure, slight 
changes in the amino acid sequence alter the efficacy and target spectrum of these 
bacteriocins, as seen with Nisin Z (271, 272). Moreover, bioengineered nisin variants have 
enhanced activity against Gram-negative pathogenic bacteria, demonstrating the potential of 
bacteriocins based therapeutic strategies (273). 
 
Bacteriocins Active Against Candida spp. 
 Bacteriocins have traditionally only been tested for their antibacterial properties. 
However, the prominence of nosocomial fungal infections resistant to traditional antifungals has 
amplified the need for alternative treatment strategies, such as bacteriocin-based therapeutics. 
A similar natural-variant of nisin A, nisin Z is produced by L. lactis NIZO22186 and significantly 
inhibits in vitro growth and hyphal morphogenesis of C. albicans (271, 274). Additionally, nisin 
Z inhibits hyphal morphogenesis and adhesion of C. albicans to oral gingival cell in an ex vivo 
oropharyngeal candidiasis (OPC) model (275). Although nisin A and Z have similar 
antimicrobial properties, there is a single residue change (H27N) that confers a superior 
diffusion rate and increases solubility at neutral pH (272). This suggests that subtle changes in 
bacteriocins can yield increased efficacy against fungal pathogens. However, other natural or 
bioengineered variants of nisin have not been reported to have activity against C. albicans.    
 Lactobacillus plantarum, another LAB associated with fermented food, produces 
multiple bacteriocins (class II) that comprise the plantaricin C11 complex, components of which 
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have been reported to have fungicidal activity against C. albicans (276, 277). The plantaricin 
C11 locus includes five operons: plnABCD, the three-component signal transduction system; 
plnEFI, two bacteriocins (PlnE and F) and immunity factor; plnJKLR, two bacteriocins (PlnJ and 
K) and immunity factors; plnMNOP, unknown function; plnGHSTUV, bacteriocin export 
machinery (278). The mechanism of action for plantaricin C11 is similar to other bacteriocins of 
its class, PlnEF and PlnJK target the membrane, create pores that disrupt the membrane 
potential and lead to bacterial cell death (269, 279). Given the difference in cell wall anatomy of 
Gram-positive bacteria and C. albicans the mechanism of action could vary. Treatment of C. 
albicans with the different bacteriocins disrupted the membrane potential, however, PlnJ had 
the greatest effect and caused release of potassium ions (K+) from cells. Additionally, all 
plantaricin peptides increased reactive oxygen species (ROS) in C. albicans, suggesting that 
plantaricins induce apoptotic cell death resulting in toxin-induced necrosis (277). 
 
Antimicrobial Peptides Active Against C. albicans 
 Part of the innate immune response, antimicrobial peptides (AMPs) are differentially 
expressed in response to pathogen-associated molecular patterns (PAMPs) that are 
recognized by pattern recognition receptors (PRRs) present on host cells. AMPs from the major 
classes, including cathelicidins, histatins, and defensins are demonstrated to be active against 
C. albicans. Interestingly, AMPs have common characteristic found in bacteriocins (cationic, 
amphipathic, positive net charge, structure stabilized by thiols), suggesting mechanisms of 
action may overlap between AMPs and bacteriocins (266, 280).   
 The antimicrobial activity of histatin-5 (Hst-5) against C. albicans is the most extensively 
examined of the AMPs that target C. albicans (281-283). Hst-5 is a cationic peptide found in 
saliva providing the first line of defense against oral pathogens such as C. albicans. The 
mechanism of action against C. albicans involves binding cell wall β-glycans and the cell wall 
protein, Ssa1 and 2 (Stress-Seventy subfamily A), that allow for translocation of Hst-5 into the 
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cell via polyamide transporters (Dur3 and 31, Degradation of URea) (284-287). Inside the C. 
albicans cell, Hst-5 has multiple intracellular targets that lead to disruption of mitochondrial 
function, production of ROS, osmotic stress due to loss of potassium ion (K+), and then 
ultimately cell death (288, 289).    
 LL-37 is a human cathelicidin that is derived by proteolysis of the CAP18 protein C-
terminus and is produced by macrophages, neutrophils, keratinocytes, and mucosal epithelial 
cells (290-292). Shown to have fungicidal activity against C. albicans, LL-37 associates with the 
cell wall and/or membrane and binds to the cell wall protein Xog1 (β-1,3-exoglucanase) that 
causes remodeling of the cell wall of C. albicans (293). Increased concentrations of LL-37 
disrupt the cell membrane causing segregation of the membrane into small vesicles disrupting 
the membrane potential due to loss of intracellular contents. The mechanism suggests that LL-
37 is able to remodel the membrane via Xog1 binding, thereby allowing for interaction with the 
cell membrane and eventually disrupting the cell membrane and causing cell death (293-295).   
 Defensins are small (3.5 to 6 kDa) with three disulfide bridges and are grouped in two 
classes, α-defensins and β-defensins (296, 297). Found in neutrophil granulocytes, α-defensin 
(HNP-1) is active against C. albicans by non-lytic ATP efflux that depletes intracellular ATP 
leading to cell death (298). β-defensins are larger and share little primary structure similarity, 
but have very similar tertiary structures (297). Expressed in environmentally exposed epithelia, 
β-defensin (hBD-3) has candidacidal activity against C. albicans by binding Xog1 which causes 
cell wall remodeling similar to LL-37, without depletion of ATP (295). 
 AMPs are generally positively charged (+2 to +9), small peptides of 10 to 50 amino 
acids that are frequently hydrophobic residues (≥30%). The structure of AMPs is important for 
antimicrobial activity and many are amphipathic helices that form pores on bacterial 
membranes (299). As reported, the mechanisms of action against C. albicans of these AMPs 
are different and often require remodeling or transient interactions with the cell wall of 
C.albicans. However, the structural conformation of these AMPs is important for interactions 
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with the cells wall and membrane that initiate the mechanism of action (294, 296, 300). 
Interestingly, sub-lethal concentrations of human LL-37, hBD-3 and Hst-5 reduce adhesion of 
C. albicans to polystyrene (293, 295, 301, 302). LL-37 and hBD-3 also inhibit hyphal 
morphogenesis at sub-lethal concentrations, suggesting that these AMPs could potentially 
have clinical relevance in biofilm prevention (295, 302). 
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Strains and Culture Conditions 
 Bacterial and fungal strains used in this study are listed in Table 2.1. Media was 
purchased from DIFCO and chemicals from Sigma, unless otherwise stated. Escherichia coli 
strains were cultured in Luria Bertani broth overnight at 37°C with antibiotics where appropriate 
using the following concentrations (µg/ml): kanamycin, 50; spectinomycin, 100; erythromycin 
300. E. faecalis strains were cultured overnight at 37°C in Brain Heart Infusion (BHI) medium or 
M9HY (304) with 100 μM glucose. Addition of antibiotics where applicable were at the following 
concentrations (µg/ml): erythromycin, 50; and rifampicin, 100. Fungal strains were propagated 
in yeast extract-peptone-dextrose (YPD) (305). All C. albicans biofilms were grown in artificial 
saliva (YNB-AS) modified from Wong et al. (306) (0.17 % YNB (w/v), 0.5 % casamino acids 
(w/v), 0.25 % mucin (w/v), 14 mM potassium chloride, 8 mM sodium chloride, 100 μM choline 
chloride, 50 μM sodium citrate, 5 μM ascorbate).  
 
Strain Construction  
 The entV mutant strain was constructed as previously described to create an in-frame 
markerless deletion using a P-pheS* counterselection system (307). Briefly, sequences 
flanking the 5’ and 3’ ends of entV were amplified by PCR. The 2 products were fused together 
by PCR with primer-introduced NotI and Pst1 sites. The resulting fragment was ligated into 
NotI/PstI digested pCJK47 vector, resulting in pCEG1. pCEG1 was electroporated into CK111 
cells, and counterselection was completed to create strain CEG1F. Deletion of entV was 
confirmed by PCR and sequencing. The entV complement strain was constructed using a 
previously described strategy in which the wild type locus is regenerated with a silent mutation 
in the gene to distinguish it from the original wild type strain (308). To generate entV*, a 
mutation (CTT) was introduced into the leucine codon TTA corresponding to amino acid 
position 50. The hyphal specific reporter strain (HWP1p::GFP) was transformed with plasmid 
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pADH1-mcherry (ADH1p::mcherry) to construct a C. albicans strain expressing both hyphal 
specific GFP and constitutive mcherry (309). 
 
C. albicans Biofilm Assay 
 The C. albicans biofilm assay was developed using a similar technique as described 
previously with the following modifications (42, 44, 310). C. albicans strains were grown 
overnight at 30°C in YPD and washed three times with phosphate-buffered saline (PBS), and 
the final OD600 was adjusted to 0.2 (~1 x 107 cell/ml) in PBS. Tissue culture treated 96 well 
polystyrene plates (Corner) or chambered polystyrene slides (Ibidi) were inoculated with C. 
albicans in PBS and incubated at 37°C for 90 minutes. Inoculated plates and slides were then 
gently washed with PBS. After removal of PBS, YNB-AS was added with 50% bacterial 
supernatant or sterile M9HY and incubated at 37°C for 24 to 48 hours. The supernatant of E. 
faecalis (OG1RF, ΔfsrB, ΔentV, ΔentV/entV) was collected as previously described (115). 
Biofilms grown with rEntV136 or sEntV68 were grown similarly with the peptide added to the 
YNB-AS medium at the appropriate concentrations and compared to HEPES or DMSO vehicle 
controls, respectively. After 24 to 48 hours of growth biofilms were washed three times with 
PBS and hyphal morphogenesis and biofilm biomass were assessed. 
 Hyphal morphogenesis was quantified in C. albicans (HWP1::pGFP) biofilms grown in 
96 well microplates by measuring GFP fluorescence, fluorescence intensity (excitation 488 nm, 
emission 520 nm) was determined using a fluorescence microplate reader (SynergyMX, 
Biotek). The relative fluorescence was calculated per well as a ration of GFP fluorescence to 
cell density (OD600) and normalized to control treated biofilms (sterile medium, HEPES, or 
DMSO). Biofilm biomass was determined by resazurin staining of C. albicans biofilms as 
previously described (311), using 0.015mg/ml of resazurin for up to 1 hour in the dark.  
 For microscopic imaging, C. albicans biofilms were gently washed in PBS, as stated 
above. Wild-type C. albicans (SC5341) were stained using 35 g/ml of calcofluor white for 5 
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minutes in the dark and imaged using 4',6-diamidino-2-phenylindole (DAPI), Fluorescein 
isothiocyanate (FITC), and differential interference contrast (DIC) filters on an Olympus IX81 
automated inverted microscope with Slidebook software (version 6.0) or Nikon A1R Confocal 
Laser automated inverted microscope system with NIS Elements (version 4.5).  
All biofilm assays were done in triplicate for three independent experiments. The 
different treatment types per experiment were compared by pairwise by Student’s t-test or One-
Way ANOVA with a P value of <0.05 considered statistically significant using GraphPad Prism 
(version 6.0).  
 
Expression and Purification of Recombinant EntV 
 Hexahistidine-tagged EntV136 was expressed as described previously (312) with the 
following modifications. The Coding regions of EntV (residues 35 to 171) were cloned in the 
pET28a vector and transformed in to E. coli BL21 (DE3) cells. Cells were lysed in lysis buffer 
(25 mM TrisHCl pH 8.0, 0.1 M sodium chloride, 1% (v/v) NP40, 10% (v/v) glycerol and 1 mM 
PMSF) by sonication for 10 minutes on an ice water bath followed by centrifugation at 10,000 x 
g at 4°C for 20 minutes.  
 The clarified lysate was then loaded on to a pre-equilibrated TALON affinity resin 
(Clontech) and washed three times with 10 column volumes each of wash buffer (50 mM 
sodium phosphate, 100 mM sodium chloride, 10 mM imidazole). The hexahistidine-tagged 
protein was eluted in elution buffer (50 mM sodium phosphate, 100 mM sodium chloride, 150 
mM imidazole) and elution fractions were collected. Samples with purified protein were 
combined and dialyzed against buffer containing 5 mM HEPES pH 7.0. The collected fractions 
were then subjected to Tricine-SDS-PAGE and analyzed by western blot using anti-His 
antibiodies (THETM, GenScript).   
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Murine Macrophage Infection 
 The activity of sEntV68 against C. albicans was evaluated in the murine macrophage 
infection model using the end point dilution assay (313, 314). Briefly, RAW264.7 murine 
macrophages were seeded in a 96-well plate with RPMI 1640 with phenol red supplemented 
with 10% fetal bovine serum (RPMI-10) at a concentration of 2.5 x 105 cells/ml per well and 
incubated overnight at 37°C with 5% CO2. After overnight growth at 30°C in YPD, C. albicans 
cultures were washed twice with PBS and resuspended at a concentration of 5 x 105 cells/ml in 
RPMI minus phenol with 100 nM of sEntV68 or DMSO and incubated at room temperature (RT) 
with shaking for 1.5 hours. The macrophage seeded 96-well plate was inoculated with serial 
dilutions of the pretreated C. albicans cell suspension. Media only controls were prepared in 
the same manner. The plates were incubated at 37°C with 5% CO2 for 15 hours. Fungal 
biomass was determined by quantification of C. albicans microcolonies using the XTT assay as 
previously described (315). Absorbance was read at 451 nm in a microplate reader 
(SynergyMX, Biotek). Assays were performed with replicates in three independent 
experiments. 
 Protection of macrophages by sEntV68 was examined by monitoring cytotoxicity of C. 
albicans on macrophages using the CytoTox96 Non-Radioactive Cytotoxicity assay (Promega) 
that measures release of lactate dehydrogenase (LDH) release (316). RAW264.7 murine 
macrophages in RPMI-10 were seeded in a 96-well plate at a concentration of 2.5 x 105 
cells/ml and incubated overnight at 37°C with 5% CO2. C. albicans cell suspensions were 
prepared at 1.5 x 106 cells/ml in RPMI minus phenol with 100 nM of sEntV68 or DMSO and 
incubated at RT with shaking for 1.5 hours. Media only controls were also prepared in the same 
manner. The macrophage seeded plates were inoculated with the pretreated C. albicans cell 
suspension and incubated at 37°C with 5% CO2 for 5 hours. LDH release was normalized to 
chemically lysed macrophages and assays were performed with replicates in three 
independent experiments.  
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 Hyphal morphogenesis of C. albicans in phagocytes was quantified after infection of 
RAW264.7 murine macrophages as described above with the following modifications. 
Macrophages were seeded on glass coverslips in 12-well plates at a concentration of 2.5 x 105 
cells/ml and incubated overnight at 37°C with 5% CO2. Overnight cultures of CEG1C 
(HWP1p::GFP; ADH1p::mcherry) were subcultured in YPD for 5 h at 30°C. Cells were collected 
and washed with PBS, and diluted in RPMI minus phenol with 100 nM of sEntV68 or DMSO to a 
concentration of 1.5 x 106 cells/ml and incubated at RT with shaking for 1.5 hours. Media only 
controls were also prepared in the same manner. The macrophage seeded glass coverslips 
were inoculated with the pretreated C. albicans cell suspension and incubated at 37°C with 5% 
CO2 for 2 hours. The media was aspirated and cells were fixed in 2.7% paraformaldehyde (pH 
7.5) for 15 minutes at 37 °C followed by washing twice with PBS. Images were captured using 
Tetramethylrhodamine (TRITC), Fluorescein isothiocyanate (FITC), and differential interference 
contrast (DIC) filters on an Olympus IX81 automated inverted microscope with Slidebook 
software (version 6.0). Cell enumeration was performed using at least 10 different fields of view 
and at least 200 cells per treatment from replicates in three independent experiments. 
 
sEntV Toxicity Assay 
 Toxicity of sEntV68 on murine macrophages (RAW 264.7) and human cervical epithelial 
cells (HeLa) was examined by monitoring cytotoxicity affects of C. albicans on macrophages 
using the CytoTox96 Non-Radioactive Cytotoxicity assay (Promega). This assay measures 
release of lactate dehydrogenase (LDH) release (32). RAW264.7 murine macrophages in 
RPMI-10 and HeLa cells in Dulbecco’s Modified Eagle Medium with high glucose and 10% fetal 
bovine serum (DMEM-HG-10) were seeded in a 96-well plate at a concentration of 2.5 x 105 
cells/ml and incubated overnight at 37°C with 5% CO2. Media from the seeded plates was 
replaced with media containing 10 μM sEntV68 and incubated at 37°C with 5% CO2 for up to 72 
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hours. LDH release was measured every 24 hours and the percentage of maximum LDH was 
calculated as a ratio of LDH from treated cells to LDH from chemically lysed cells. 
 
Oropharyngeal Candidiasis Model 
 The efficacy of sEntV68 was tested in the oropharyngeal candidiasis (OPC) model as 
previously described (317). Mice were immunosuppressed by injecting cortisone acetate 
subcutaneously in the dorsum of the neck at a concentration of 225mg/kg of body weight one 
day before inoculation, and subsequently on days 1 and 3 of the infection. Before inoculation, 
with C. albicans mice were anesthetized with an intraperitoneal injection of 0.1 ml/10g of body 
weight with 10mg/ml ketamine and 1 mg/ml xylazine and placed on pre-warmed hot water 
blankets. C. albicans was grown at 30°C in YPD broth overnight and sub-cultured twice before 
washing with PBS twice and preparing cell suspensions in Hanks’ balanced salt solution 
(HBSS) at 1 x 106 cells/ml. Calcium alginate swabs were immersed in the C. albicans 
suspension with 100 nM sEntV68 or DMSO for 5 minutes and then used to inoculate the mice 
sublingually for 75 minutes.  
 The mice were monitored continuously for signs of waking up (movement of extremities 
and/or blinking of the eyes) and were given additional doses of ketamine, as necessary 
(without xylazine, 50 mg ketamine/kg of body weight). After inoculation mice were treated with 
100 nM of sEntV68 or DMSO in the drinking water for the remainder of the experiment. Mice 
were euthanized at 3 and 5 days post-inoculation. The tongues were excised for tissue 
histology and assessment of the fungal burden.  
 Tongues were fixed in zinc-buffered formalin followed by paraffin embedding. Thin 
sections of the tongues stained with periodic acid–Schiff (317). Tissue histology was observed 
using a light microscope. Images were captured at 40X and histology quantified by measuring 
the percentage of infected epithelium relative to the entire epithelial area (318). The complete 
epithelial area and infected epithelium were measured from 40X images taken of the entire 
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tissue section of each sample. For each image the total area of epithelium and infected 
epithelium were measured using Image J (version 1.5). Measurements were totaled and 
expressed as a percentage of total infected epithelium relative to the entire totaled epithelial 
area. 
 For examination of fungal burden, quantitative PCR (qPCR) was utilized by amplifying a 
269 basepair fragment of internal transcribed spacer 2 (ITS2) between the 5.8S and 28S 
ribosomal RNA genes of C. albicans using 5.8S forward primer and 28S-1 reverse primer 
(Table 2.1) (319, 320)38,39]. DNA was extracted using the Yeast DNA Extraction Kit (Thermo 
Scientific) according to the protocol with the following modifications. A portion of tongue from 
each mouse was homogenized in 300μl of Y-PER reagent for 8–10 second increments with 
incubation on ice until samples were completely homogenized followed by incubation at 65°C 
for 10 minutes. Samples were centrifuged at 13,000 x g for 10 minutes, supernatant discarded, 
400ul of Reagent A and 400ul of Reagent B was added, vortexed, and incubated at 90°C for 3 
hours. After treatment protein removal agent DNA was precipitated with isopropyl alcohol and 
washed with 70% ethanol and resuspended in sterile ultra pure water.  
  The ITS2 fragment was amplified from the DNA extractions and qPCR was performed 
with a CFX96TM Real-Time System with a C1000 TouchTM thermal cycler (BioRad). A standard 
curve was generated using C. albicans genomic DNA ranging from 0.5–5000 pg. C. albicans 
DNA was quantified using FastStart Universal SYBR Green master mix with ROX (Roche). 
Reactions were set-up according to the manufacturer’s recommendations. To screen for 
contamination and background fluorescence during qPCR amplification, no template controls 
were used. Non-infected mouse tongues and extraction-negative controls were processed in 
parallel with tissue samples to test for possible contamination during homogenization and 
extraction.  
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Proteolytic Cleavage of rEntV136 by GelE 
 Since EntV136 is larger than expected based on size exclusion centrifugation of the 
inhibitory activity and GelE and SprE cleave E. faecalis surface and secreted proteins, 
proteolytic cleavage of rEntV136 by GelE was examined. Proteolytic activity of GelE was 
examined as previously described by Pinkston et al. (321). rEntV136 (30 μg/ml) was incubated 
with increasing concentrations of purified GelE (1.5, 4.5, 15, and 30 μg/ml) in PBS at 37°C for 
one hour. Samples were boiled at 100°C for five minutes in SDS-PAGE sample buffer with 
BME to terminate the reaction. To evaluate cleavage of rEntV136, reactions were subjected to 
Tricine-SDS-PAGE and stained with SYPRO Ruby (Lonza) protein gel stain and visualized 
using a 300 nm UV transilluminator (322). 
 
Homozygous Deletion Mutant Library Screens 
 To identify possible inhibitory targets of the morphogenesis pathways and stress 
response pathways a C. albicans mutant library of homozygous deletions in non-essential 
transcription factors was screened for resistance to E. faecalis supernatant. Biofilms were 
grown in a 96-well microtitered plates in YNBM as described above. Biofilm biomass was 
quantified using resazurine (Sigma), as a measure of biofilm biomass and was quantified using 
a fluorescence plate reader. E. faecalis supernatant was harvested as described above and 
50μl added to 96 well plates with 1μl of mutant culture and 50μl YNBAS. Biofilms were grown 
for 24 hrs at 37°C with shaking (200 rpm) (42). The 50μl of E. faecalis supernatant was 
replaced for 50μl of sterile bacterial medium as non-treatment controls for each mutant strain. 
Resistance to supernatant was determined by comparing treated cells to non-treated controls. 
Wildtype (SC5314) and the respective parent strains (SN152 and Day286) were tested in the 
same manner. Statistically significance differences between treated cells and non-treated 
controls was determined by Student’s t-test. Mutant strains that had no statistically significance 
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differences between treated cells and non-treated controls were test in a secondary screen 
using the in vitro biofilm protocol described above. 
 
sEntV68-FITC localization on C. albicans  
 C. albicans SC5314 expressing constitutive mcherry (ADH1p::mCherry) were grown 
overnight at 30°C in YPD with aeration. Overnight cultures were sub-cultured in YPD for 5 h at 
30°C and washed three times with phosphate-buffered saline (PBS). Washed cells where 
transferred to chambered polystyrene slides (Ibidi) at a final OD600 of 0.2 (~1 x 107 cell/ml) in 
YPD with or without 100nM of sEntV68. Cells were grown for 1 hour at 30°C or 37°C with 
aeration. To observe sEntV68 localization on hyphal cells, cells were grown at 37°C for 1 hour 
prior to addition of sEntV68. sEntV68 localization was observed by fluorescence microscopy 
(Olympus IX81) using slidebook 6 (3i, Intelligent Imaging Innovations). 
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Table 2.1: Strains and Plasmids 
Candida albicans Strains 
Strain Designation Relevant genotype/characteristic Parent 
Source or 
reference 
SC5314 Wild-type Prototroph -   (323) 
DHC271 HWP1-GFP ura3/ura3ENO1/eno1::HWP1p-GFP-URA3 SC5314 (324) 
CEGC1 
HWP1-GFP ADH1-
mCherry 
ura3/ura3ENO1/eno1::HWP1p-GFP-URA3 
RPS10/rps10::ADH1p-mCherry-SAT1  
DHC271 This study 
Day286 Parent 
ura3::imm434/ura3::imm434 
his1::hisG/his1::hisG 
arg4::hisG/arg4::hisG 
pRS-ARG4-URA3 
BWP17 (325) 
SN152 Parent 
arg4::dpl200/arg4::dpl200 
his1::dpl200/his1::dpl200 
leu2::dpl200/leu2::dpl200 
URA3/ura3 
RM1000 (326) 
JC50 hog1Δ/Δ 
ura3/ura3 
his1/his1 
hog1∆::LoxP/hog1∆LoxP-HIS1-LoxP 
RPS10/rps10::CIp20 
 (327) 
JC52 hog1Δ/HOG1 
ura3/ura3 
his1/his1 
hog1∆::LoxP/hog1∆LoxP-HIS1-LoxP 
RPS10/rps10::CIp20-HOG1 
 (327) 
  Other Fungal Strains   
Strain Species Relevant genotype/characteristic  
Source or 
reference 
MYA3404 Candida tropicalis Prototroph  (328) 
CLIB298 Candida glabrata Prototroph  (328) 
J941367 Candida parapsilosis Prototroph  (328) 
Enterococcus faecalis Strains 
Strain Designation Relevant genotype/characteristic Parent 
Source or 
reference 
OG1RF Wild-type Gel+ Spr+ RfR FaR OG1 (329) 
TX5266 ΔfsrB 
fsrB in-frame deletion mutant (bp 79 to 684);  
Gel- Spr- RifR FaR KanR 
OG1RF (201) 
CK111 Conjugative donor upp4::P23repA4, SpR OG1Sp (307) 
CEGF1 ΔentV Markerless deletion of entV; RfR FaR OG1RF This study 
CEGF2 ΔentV/ entV 
Reconstituted entV with a silent nucleotide 
change, Δef1097 [entV*], RfR FaR 
CEGF1 This study 
Escherichia coli Strains and Plasmids 
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Strain Relevant genotype/characteristic 
Source or 
reference 
EC1000 E. coli cloning host for pCJK47-based plasmids; provides RepA in trans (330) 
DH5α E. coli cloning host for routine cloning Invitrogen 
BL21 
(DE3) 
E. coli cloning host for routine cloning, suitable for protein expression Invitrogen 
CEGE1 BL21 (DE3) with pET28a containing entV136 This study 
pCJK47 Plasmid for markerless exchange, oriTpCF10 and P-pheS*; EmR (307) 
pET28a 
Recombinant expression vector, N-terminal His•Tag/thrombin/T7•Tag configuration 
plus an optional C-terminal His•Tag sequence, IPTG or lactose inducible 
Novagen 
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CHAPTER 3: 
 
The Enterococcus faecalis bacteriocin EntV inhibits hyphal morphogenesis, biofilm 
formation, and virulence of Candida albicans 
 
 
 
 
 
Portions of this chapter are based on my first author publication. I have received permission to 
reproduce data or text from this article through license number. I have contributed significantly 
to this publication. The article is listed for reference: Graham, C. E., M. R. Cruz, D. A. Garsin, 
and M. C. Lorenz. 2017. Enterococcus faecalis bacteriocin EntV inhibits hyphal 
morphogenesis, biofilm formation, and virulence of Candida albicans. Proc. Natl. Acad. Sci. 
U.S.A. 114: 4507–4512 (303). 
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Introduction: 
 The mucosal surfaces, such as the orogastrointestinal tract of mammals, are ideal 
niches for microorganisms and it is here where the balance between microbe-microbe 
interaction and the host play an important role (331-333). Most of the microorganisms in the 
orogastrointestinal tract are benign or beneficial to the host. However, the status of the host is a 
major determinant of microbial pathogenesis. As discussed previously, microorganisms 
typically found as part of orogastrointestinal tract microbiome can cause life-threatening 
infections. In order for this to occur the microorganisms must cross host protective barriers 
and/or evade the immune response and must be capable of colonizing other host niches 
throughout the body (9).  
 Although E. faecalis and C. albicans are part of the orogastrointestinal microbiome, they 
are among the most important and problematic, opportunistic nosocomial pathogens (186, 235, 
334). When the host defenses are compromised and/or the microbiome is altered, both are 
capable of crossing anatomical barriers and evading the host immune response (335). 
Furthermore, the ability to form biofilms is an important virulence trait of both E. faecalis and C. 
albicans, as both are capable of forming biofilms on biotic or abiotic surfaces that complicate 
treatment strategies (39, 336). Specifically, C. albicans forms formidable biofilms that can 
exceed 200µm in depth and is often found in polymicrobial biofillms with bacteria that have 
enhanced resistance to anti-microbial drugs and immune surveillance (39, 42, 149, 337).  
 Since C. albicans and E. faecalis occur in overlapping niches as commensals and are 
commonly co-isolated during infection, it is plausible that diverse interactions exist between 
these microbes. Using a Caenorhabditis elegans model infections model, we demonstrated 
antagonistic interactions between C. albicans and E. faecalis (115). Attenuation of virulence is 
observed in both microorganisms during co-infection of Caenorhabditis elegans. As illustrated 
in Figure 3.1, these findings demonstrate a commensal-like interaction within this model host; 
co-colonization with both microbes does not cause disease unlike individual colonization. 
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Further characterization of the activity by which E. faecalis inhibited C. albicans virulence, 
identified a secreted factor that exerts its protective effect by inhibiting C. albicans hyphal 
morphogenesis and biofilm formation (115, 338).  
 Taking into account the interactions observed in the C. elegans model, environments 
where these commensal-like interactions might occur in a more relevant mammalian host were 
considered. C. albicans infections of the oral cavity occur in immunocompetent and 
immunosuppressed individuals (339). Oropharyngeal candidiasis (OPC), a superficial fungal 
infection of the oral cavity, is one such infection (339-341). OPC most commonly occurs in 
immunocompromised individuals, such as those that on immunosuppressant drugs, 
chemotherapy, or suffering from HIV/AIDS (342-344). In immunocompetent individuals, some 
common risk factors include use of dentures, corticosteroid inhalers, cigarettes and broad-
spectrum antibiotics (345-347). 
 Formation of thick white plaques (biofilms) of C. albicans on the surface of the tongue, 
buccal mucosa, soft palate and pharynx are the clinical manifestations of OPC (347). While 
superficially infecting the oral cavity, C. albicans invades the oral epithelial cells by inducing 
endocytosis of C. albicans by the epithelial cells and active penetration of epithelial cells (348-
351). Invasion of the oral epithelial by C. albicans causes cell damage that elicits production of 
the proinflammatory response that in turn stimulates production of AMPs and recruitment 
professional phagocytes (339, 341). Professional phagocytes, neutrophils and macrophages, 
are crucial elements of the innate immune response to C. albicans during oral infections (352, 
353). Depletion of neutrophils and elimination of macrophages in a murine OPC model 
increased susceptibility to C. albicans infection (352).  
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Figure 3.1: E. faecalis-C. albicans interactions during infection of Caenorhabditis 
elegans.  
During mono-infection (top, left) C. albicans has pathogenic association with the host, primarily 
through the production of hyphal cells. As seen in the scanning electron (SEM) image (bottom, 
left) C. albicans forms hyphal cells that are capable of disseminating throughout the nematode. 
In the presence of E. faecalis during co-infection (top, right), C. albicans has commensal like 
association with the nematode. Apparent in the SEM image (bottom, right) C. albicans and E. 
faecalis are able to colonize the GI tract of the nematode and hyphal morphogenesis is 
inhibited. Hyphal morphogenesis is inhibited by the presence of E. faecalis via production of a 
secreted factor(s) (115).  
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Here I identify the E. faecalis secreted inhibitory factor as EntV, a secreted bacteriocin with 
reported antibacterial activity. When synthetically produced, this peptide inhibited C. albicans 
hyphal morphogenesis and biofilm formation at sub-nanomolar concentrations. Furthermore, 
EntV was active against mature biofilms, reducing the depth and biofilm biomass. EntV 
significantly protected murine macrophages against C. albicans infection and was protective in 
a murine model of OPC. As the rise of drug-resistant fungal infections threatens to undermine 
the current small arsenal of available treatments, I propose that EntV, or similar compounds, 
may offer a viable therapeutic alternative, either alone or in combination with existing antifungal 
agents. 
 
Results: 
E. faecalis supernatant inhibits C. albicans hyphal morphogenesis and biofilm formation 
E. faecalis secretes an inhibitor of C. albicans virulence and biofilm formation (115). To 
facilitate identification of this inhibitor, I developed a C. albicans in vitro biofilm model in which 
cells are grown on a polystyrene substrate in an artificial saliva medium (YNBAS, adapted from 
(306)). This media supported biofilm growth over 24 hours (Fig. 3.2A and B), while 
supplementation with supernatant from E. faecalis cultures decreased both biofilm biomass and 
hyphal morphogenesis as compared to biofilms grown in medium alone (Fig. 3.2). The E. 
faecalis-mediated inhibition was observed microscopically in biofilms stained with calcofluor 
white (Fig. 3.2A and B) and quantitated using the redox reactive dye resazurin to measure 
biomass (311) (Fig. 3.2C). The reduction in hyphal formation was assayed using a reporter 
strain expressing a transcriptional fusion of the hyphal-specific HWP1 gene to GFP 
(HWP1p::GFP) (Fig. 3.2D-F) (324). A direct correlation between decreases in HWP1-induced 
fluorescence (Fig. 3.2F) and biofilm biomass (Fig. 3.2C) was  
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Figure 3.2: E. faecalis supernatant inhibits C. albicans hyphal morphogenesis and 
biofilm formation.  
C. albicans biofilms grown for 24 hours in YNBAS. Representative images of C. albicans (strain 
SC5314) biofilms in the (A) absence and (B) presence of E. faecalis supernatant and stained 
with calcofluor white. (C) Biofilm density was quantified by measuring resazurin fluorescence. 
Representative images of C. albicans hyphal reporter strain (HWP1p::GFP) in the (D) absence 
or (E) presence of E. faecalis supernatant. (F) Hyphal morphogenesis was quantified by 
measuring GFP fluorescence as a ratio to the OD600.  Experiments were performed three times 
and analyzed using Student’s t-test (****, p<0.0001).  
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observed, which is in agreement with previous studies demonstrating that hyphal deficient 
mutants have reduced biofilm biomass (354, 355).  
 
EntV inhibition of hyphal morphogenesis and biofilm formation in C. albicans 
 Our previous studies in the C. elegans infection model suggested that the secreted 
inhibitor is regulated by the Fsr two-component quorum sensing system mediated by the 
Gelatinase Biosynthesis Activating Pheromone (GBAP) (115, 338). The Fsr system regulates a 
number of virulence-related traits, including secreted proteases GelE and SprE, as well as a 
bacteriocin identified systematically from the genome of strain V583 as ef1097 (356, 357). 
ef1097 encodes a 170 amino acid pre-pro-peptide, and cleavage of the secretion leader 
sequences results in the export of a 136-residue pro-peptide that has bactericidal activity 
against Gram-positive bacteria (245, 358). Bacteriocins are typically named after the strain in 
which they are found, and thus the ef1097 gene product was called enterococcin V583 and 
enterocin O16 in previous publications (245, 358). However, because the gene is present in all 
E. faecalis strains sequenced to date (245), we propose to name the gene product EntV, for 
enterocin originally found in V583.  
I hypothesized that EntV is the secreted inhibitor of C. albicans hyphal morphogenesis 
and biofilm formation and tested this genetically. I constructed a deletion mutant of entV and 
tested the supernatant for activity against C. albicans biofilms using the hyphal specific reporter 
strain (HWP1p::GFP). Indeed, the biofilm inhibitory activity was lost in supernatants derived 
from the entV mutant strain relative to those from the WT E. faecalis strain (Fig 3.3A), 
confirming that EntV is necessary for the inhibition of biofilm formation. The mutant strain was 
complemented by introducing the gene back into the endogenous locus with a silent mutation 
to distinguish it from the original wild type strain (308). Supernatant from the complemented 
strain inhibited biofilm formation as well as that of wild type E. faecalis.  
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Figure 3.3: EntV inhibition of hyphal morphogenesis and biofilm formation in C. 
albicans.  
(A) C. albicans SC5314 biofilms grown for 24 hours in YNBAS with sterile media (M9HY) or 
spent supernatant from wild-type and mutant E. faecalis strains. Hyphal morphogenesis was 
quantified by measuring GFP fluorescence as a ratio to the OD600. The experiment was 
performed three times and analyzed using one-way ANOVA (***, p<0.0008). (B) Biofilms were 
grown with increasing concentrations of rEntV136 or sEntV68 and the IC50 calculated at 1000 nM 
and 0.3 nM, respectively.  
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To test if EntV136 was sufficient for the inhibitory activity, rEntV136 was expressed and 
purified from E. coli with a hexa-histidine tag (Table 2.1). I detected rEntV136 biofilm inhibitory 
activity with an IC50 of ~1000nM (Fig. 3.3B). Thus, the genetic and biochemical evidence 
suggests that EntV is both necessary and sufficient for inhibition of C. albicans biofilm 
formation. The 136-amino acid EntV is larger than the 3-10 kDa indicated by our preliminary 
characterization. However, recent work from Dundar et al. suggests that EntV136 is further 
processed in a GelE-dependent manner to a 7.2  kDa peptide encompassing the 68 carboxy-
terminal amino acids (EntV68) (245). This mature form has a predicted disulfide bond that 
encompasses nearly the entire length of the active protein (from amino acid 4 to 65 of the 68 
amino acid peptide) that is necessary for its anti-bacterial activity (245, 358). Attempts to 
express and purify EntV68 were unsuccessful due to apparent toxicity in E. coli. To surmount 
this obstacle, the peptide was synthetically produced (sEntV68) in a form that included a 
disulfide between the cysteine residues. As seen in Fig. 3.3B, sEntV68 inhibited biofilms with an 
IC50 of 0.3nM, and therefore was ~3,000-fold more active than the unprocessed form of the 
peptide. 
 
Characterization of sEntV68 inhibitory activity 
To investigate the dynamics of C. albicans biofilms in the presence of sEntV68 I turned 
to confocal microscopy, with which I could generate a 3-D projection allowing me to measure 
the overall biofilm depth. When formed in the nutrient-poor artificial saliva medium, control 
biofilms were 25-30 µm thick after 24 hours, but only 5-10 µm thick in the presence of sEntV68, 
roughly the length of a C. albicans yeast cell (Fig.3.4A and B). I next examined the 
effectiveness of sEntV68 against mature biofilms grown for 24 hours. As viewed by confocal 
microscopy, when biofilms that had developed for 24 hours were treated with sEntV68, a 
reduction in biofilm depth from ~30μm to ~15μm (Fig. 3.4A) was observed, indicating  
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Figure 3.4: Characterization of sEntV68 inhibitory activity.  
C. albicans SC5314 biofilms were grown with 0.01% DMSO or 100 nM sEntV68 added at 
different time points during biofilm formation (‘-‘, not added; ‘0hr’, added at the beginning of the 
experiment. (A) Representative image of 24 hour and 48 hour biofilms observed by confocal 
microscopy. (B) Hyphal morphogenesis was quantified by measuring GFP fluorescence as a 
ratio to the OD600 for three separate experiments (**, p=0.0058; ***, p=0.0005; ****, p<0.0001).  
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that this peptide could dismantle mature biofilms. Correspondingly, when the HWP1p::GFP 
reporter was used to measure hyphal morphogenesis, a decrease in signal was observed at 48 
hours following treatment with sEntV68 at 24 hours compared to biofilms grown with the vehicle 
control after 24 and 48 hours of growth (Fig. 3.4B). 
 
Protection of Murine Macrophages by sEntV68 during C. albicans infection 
C. albicans is readily phagocytosed by murine macrophages, whereupon it activates a 
complex transcriptional and morphogenetic program that promotes fungal survival and results 
in hyphal-dependent lysis of the macrophage (316, 359, 360). I asked whether sEntV68 could 
protect phagocytes from fungal-dependent killing. In these experiments, C. albicans was 
incubated with sEntV68 for 1.5 hours before being added to the macrophages. sEntV68 was also 
added to the macrophage cell culture medium immediately prior to infecting with C. albicans. A 
decrease in C. albicans survival was observed when the macrophage infection was carried out 
with sEntV68 as compared to the control infections (Fig. 3.5A), suggesting that sEntV68 works in 
synergy with murine macrophages to make C. albicans more sensitive to macrophage attack. 
Additionally, I observed a significant decrease in macrophage cytotoxicity in the presence of 
sEntV68 compared to the controls (Fig. 3.5B), suggesting that sEntV68 protects murine 
macrophages during C. albicans infection. To assess whether sEntV68 inhibits hyphal 
morphogenesis within macrophages I used a hyphal specific reporter strain (HWP1p::GFP) 
constitutively expressing mCherry (ADH1p::mCherry). Cells treated with sEntV68 had a 
decrease in hyphal growth and GFP fluorescence as compared to control treated cells (Fig. 
3.5C and D). No toxicity of the peptide towards macrophages or HeLa cells was observed (Fig. 
3.6A and B). Taken together these results suggest that sEntV68 protects murine macrophages 
by inhibition of C. albicans hyphal morphogenesis. 
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Figure 3.5: Protection of Murine Macrophages by sEntV68 during C. albicans infection. 
(A) Murine derived macrophages (RAW264.7) were infected with C. albicans (HWP1p::GFP, 
ADH1p::mCherry) at an MOI of one for one hour with 0.01% DMSO or 100nM sEntV68 followed 
by fixation with paraformaldehyde and visualized by fluorescence microscopy. (B) 
Filamentation of phagocytosed cells was scored after 2 hours of co-culture. At least 200 cells in 
at least 10 different fields of view were counted per replicate and the experiment was repeated 
three times. (C) Macrophage killing was evaluated using the LDH cell toxicity assay and the 
percentage of killed macrophages calculated. (D) C. albicans survival in murine macrophages 
was assessed using the XTT cell viability assay and the percent survival was calculated. 
Statically significant differences were calculated using one-way ANOVA (* p<0.02).  
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Figure 3.6: Activity of sEntV68 in mammalian cells.   
Lactate dehydrogenase (LDH) was measured from (A) Murine macrophages (RAW 264.7) and 
(B) Human cervical epithelial cells (HeLa) exposed to 10 μM sEntV68 or 1% DMSO for up to 72 
hours. Cell toxicity was evaluated using the LDH release assay and the percentage LDH 
calculated for replicates of three separate experiments. 
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Efficacy of sEntV68 in the Murine Oropharyngeal Candidiasis Model 
Recall, that C. albicans grows on the mucosal surfaces of the oral cavity as part of the 
normal microflora. However, in patients with defective immune responses it can cause a 
superficial infection and invade the epithelial layer causing oropharyngeal candidiasis (OPC) 
that leads to increased morbidity (348-351). To test the efficacy of sEntV68 in host relevant 
infection model, I used a murine OPC model (317). In this model, mice were given a sublingual 
inoculation of C. albicans and then given sEntV68 or DMSO in sterile drinking water for up to 5 
days. The mice were euthanized and tongues excised at day 3 and day 5 to examine the 
histology and fungal burden. Control mice showed classical signs of OPC, including extensive 
invasion of the epithelium by fungal hyphae, disruption of the outer layers of epithelial cells, and 
infiltration of neutrophils (Fig. 3.7A). In contrast, mice that were treated with 100 nM sEntV68 
has significantly reduced invasion; most fungal cells were in the yeast or pseudohyphal form, 
indicating that the peptide can inhibit morphological differentiation in vivo as well (Fig 3.7A). To 
provide a quantitative measure of the epithelial invasion, I scored the proportion of the 
epithelium infected in multiple tongues from control or sEntV68-treated mice, as recently 
described (318). This data demonstrates a clear difference in the extent of epithelial damage 
between treated and control animals (Fig. 3.7B). Finally, I assessed fungal burden on the 
tongues. Because of the significant morphological differences in the two conditions, I 
considered that colony forming unit plating would not accurately reflect differences in burden 
between the primarily yeast morphology in the sEntV68-treated animals and the multinucleate 
and highly adherent hyphae in the controls. Instead, I quantitated fungal DNA using qPCR as 
described (319, 320), which showed a significant decrease in fungal burden in peptide-treated 
mice relative to control mice (Fig. 3.7C). These results indicate that sEntV68 is effective in a 
complex mammalian infection model that simulates clinically relevant infection conditions. 
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Figure 3.7: sEntV68 is protective in a murine OPC model.   
Immunosuppressed mice were inoculated sublingually with C. albicans SC5314 with 0.01% 
DMSO or 100 nM of sEntV68.  Water containing sEntV68 (100 nM) or vehicle (DMSO) alone was 
provided ad libitum. After three or five days, mice were euthanized and the tongues were 
excised for histological examination of (A) DMSO control or (B) sEntV68-treated mice. Red 
arrows indicate hyphal cells and black arrows indicate yeast cells.  (C) The percentage of the 
epithelial surface showing evidence of fungal invasion was calculated for control and treated 
tongues. (D) DNA was extracted from the tongues and the fungal burden was estimated from 
qPCR amplification of the 5.8S ITS2 region. Statistically significant differences were calculated 
using one-way ANOVA (**, p<0.01) 
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nearly the entire protein. Between the cysteines, the structure
of the mature form of EntV ispredicted in silico to consist of
two helical elements, separated by a flexible loop region (25,
27). The bactericidal activity of EntV is not due to lysis and
there isno evidenceof an immunityprotein, so themechanism
remains enigmatic (25, 27). Likewise, the mechanism of the
antihyphal activity is unclear, although it does not lyse fungal
cellseither. In fact, growth and chemical sensitivity of C. albi-
canscells is unaffected, even when exposed to concentrations
four logshigher than the IC50. Thus, EntV exertsa true anti-
virulence effect on thisimportant fungal pathogen. It hasbeen
speculated that therapeuticsthat target virulencemight be less
likely to elect for resistance. In support of this idea, a small
molecule also exhibiting C. albicans biofilm and hyphal
morphogenesis-inhibiting properties did not induce resistance
after repeated exposure (40).
In the OPC model, EntV reduced, but did not eliminate,
fungal col nization. I c trast, fungal invasion of the epi he-
liumand inflammation, which are responsible for the pathology
of OPC, were almost entirely absent. Thus, in the presence of
EntV, C. albicansrevertstoabenigncommensal interaction with
thehost. Wehavespeculated that thesetwospeciesmight find it
advantageous to suppress virulence attributes in favor of colo-
nization (10); indeed, C. albicanspromotesE. faecaliscoloniza-
tion in thegastrointestinal tract (41, 42). Thi proposal iscounter
to studies that suggest these species are commonly isolated to-
gether in manyclinical samples(6) but this, too, might represent
a coordination of behavior through sensing host weaknesses to
switch cocommensal to copathogen. In support of this notion,
EntV68 doesnot affect hyphal growth stimulated bymammalian
serum, the strongest inducing factor (17) and an obvious host
signal during disseminated infection. A precedent for this ap-
parent contradiction is seen in the interaction between C. albi-
cansand P. aeruginosa, speciesthat areantagonistic in vitro (13,
43), but associated with significantly worse clinical outcomes
when found together in several clinical settings (44, 45). It is
possible that someof theprotective effectsof EntV in theOPC
model aredueto itsactivityagainst other bacterial speciesin the
mouth, although we would expect this to enhance fungal colo-
nization rather than suppress it. We are thusonly beginning to
understand the complex interactions among the microbiota and
their varied effects on the human host, but the knowledge is
likely to have important impacts on the development of
novel antimicrobials.
Materials and Methods
Microbiological and Molecular Biological Methods. Candida and Enterococcus
strainsused in thisstudy are listed in Table S1. Standard culture media were
used for routine propagation, asdescribed in SI Materialsand Methods. The
entV mutant strain was constructed as described to create an in-frame
markerless deletion by using a P-pheS* counterselection system (46) and
complemented by using a reported strategy to regenerate the wild-type
locus (47). The recombinant hexahistidine-tagged 136-aa EntV propeptide
wasexpressed from pET28a in Escherichia coli BL21 and purif ied on TALON
resin, as described (48). Attempts to purify the fully active 68-aa peptide
from E.coli wereunsuccessful; thepeptide wassynthesized with thedisulfide
bond (Lifetein). The hyphal-specificHWP1p-GFPreporter strain DHC271 (21)
expressing a constitutive mCherry was generated via transformat ion with
plasmid pADH1-mCherry (49).
In Vitro Biofilm Assays. Biofilm assaysin conditionsmimicking the oral cavity
weremodified frompublished reports(15, 50, 51) by using an artificial saliva
media [0.17% Yeast Nitrogen Base (vol/vol), 0.5% casamino acids (vol/vol),
0.25% mucin (vol/vol), 14 mM potassium chloride, 8 mM sodium chloride,
100 μM choline chloride, 50 μM sodium citrate, 5 μM ascorbate] adapted
from ref. 19. This media was supplemented with conditioned bacterial su-
pernatant or recombinant or synthetic peptide, as indicated. Biofilm devel-
opment was allowed to proceed for 24–48 h and then assessed in three
ways: by estimating biomassusing the redoxdye resazurin, asdescribed (20),
by measuring fluorescence from the HWP1p-GFP hyphal-specific reporter
strain (21), or through confocal microscopy.
Nematode Infection Model. C. elegans glp-4(bn2);sek-1(km4) nematodes
were propagated by using standard techniques on E. coli strain OP50 on
nematode growth medium (NGM) agar (52). The liquid infection assay was
performed asdescribed (17, 28); briefly, young adultswere incubated for 4h
on solid medium with the wild-type C. albicans SC5314 strain, then the
wormswere collected, washed, and transferred to six-well platescontaining
20% Brain Heart Infusion (BHI) and 80% M9W, after which viability was
assayed daily. Filamentat ion of C. albicanswithin the wormswasscored via
microscopic analysis.
Murine Macrophage Infection. To assesswhether EntV68 protectsphagocytes
from fungal-induced damage, we used a coculture assay in which C. albicans
cells were incubated with RAW264.7 murine macrophage-like cells as de-
scribed (32). Fungal viability was assessed by using a modified end-point di-
lution assay in which respiratory activity ismeasured using a tetrazolium dye,
XTT (53, 54). Lactate dehydrogenase wasassayed by using the Cytotox96 kit
(Promega). C. albicansmorphology wasassayed microscopically.
Murine Oropharyngeal Candidiasis Model. Adult BALB/c mice were immuno-
suppressed with subcutaneous injections of cortisone acetate before sub-
lingual inoculation with C. albicans according to Solis and Filler (36). Mice
were given EntVor vehicle in drinking water ad libitum. Three and five days
after inoculation, micewereeuthanized and the tonguesexcised and halved
longitudinally. Part of the tongue was processed for histopathological
analysis, whereas the rest was homogenized for assessment of fungal bur-
den via qPCR. DNA was extracted by using the Yeast DNA Extraction Kit
(Thermo Scientific), and the Internal Transcribed Spacer (ITS1) of the rDNA
genes was amplified as described (38, 39). Experimentswere performed in
accordance with protocols approved by the Animal Welfare Committee of
the University of TexasHealth Science Center at Houston.
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Fig. 6. sEntV68 isprotective in a murine OPCmodel.
Immunosuppressed micewere inoculated sublingually
with C. albicansSC5314 with 0.01% DMSOor 100 nM
sEntV68. Water containing sEntV68 (100nM) or vehicle
(DMSO) alonewasprovided ad libitum. After 3or 5d,
mice were euthanized and the tongueswere excised
for histological examination of DMSO control (A) or
sEntV68-treated (B) mice. Red arrowheads indicate
hyphal cells, and black arrowheadsindicateyeast cells.
(C) The percentage of the epithelial surface showing
evidenceof fungal invasion wascalculated for control
and treated tongues. (D) DNA wasextracted from the
tongues and the fungal burden was estimated from
qPCRamplification of the5.8SITS2region. Statistically
significant differences were calculated by using one-
way ANOVA (**P< 0.01).
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Discussion: 
 I observed a distinct antagonistic interaction between E. faecalis and C. albicans, in 
which hyphal morphogenesis, an important virulence factor, is inhibited by a secreted 
bacteriocin, EntV. Hyphal morphogenesis is important for many aspects of C. albicans 
pathogenicity, including biofilm formation, resistance to phagocytes, and dissemination through 
tissues (102, 361, 362). The implications of this inhibitory activity are clearly seen in the 
decreased virulence of C. albicans cells exposed to this peptide in murine macrophages, and in 
the mouse OPC model.  
 Biofilm-related infections pose numerous clinical challenges. Biofilms provide a 
measure of protection to the microbes encased within them from phagocytic attack and 
antibiotics (20). Protection of persister cells within the biofilm allows C. albicans to disseminate 
to distant sites, seeding relapses and systemic infections (88). Biofilms of C. albicans are 
robust and form both on implanted medical devices (catheters, heart valves, dentures) and on 
epithelial surfaces (OPC) (39). Our in vitro experiments were designed to model the oral cavity, 
and I observed biofilms exceeding 50 µm in depth; in other media conditions, they can be 
greater than 200 µm thick. Often, device removal is the only effective treatment option, though 
this may not be feasible or desirable given a patient’s underlying conditions. Agents that 
directly disrupt biofilms would be very useful chemotherapeutics in conjunction with existing 
drugs. Our work suggests that EntV is a candidate anti-biofilm agent. 
Currently, nearly all antimicrobials in clinical use work by killing or preventing the growth 
of the infectious agent.  Certainly, this is true for C. albicans. There are presently only three 
families of commonly used antifungal drugs, polyenes, azoles and echinocandins, all of which 
target the cell membrane or the cell wall (80, 363). Resistance to this limited arsenal of 
antifungals is a growing problem (364). It has long been speculated that therapeutics that target 
virulence might effectively treat infection and not select for resistance as strongly as traditional 
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antimicrobials. In support of this idea, a small molecule also exhibiting C. albicans biofilm and 
hyphal morphogenesis-inhibiting properties did not induce resistance after repeated exposure 
(365). 
 Many clinical Candida infections are polymicrobial. In one survey of these polymicrobial 
infections, the most common bacterial co-habitant was E. faecalis (109). In contrast, our work 
suggests that these two microbes have evolved a relationship in which one inhibits a key 
virulence trait of the other. A precedent for this apparent contradiction is seen in the interaction 
between C. albicans and P. aeruginosa, species that are antagonistic in vitro (126, 128), but 
are associated with significantly worse outcomes when found together in patients, including the 
lungs of cystic fibrosis patients, during ventilator-associated pneumonia, and in burn trauma 
(123, 124).   
 I previously speculated that the presence of both C. albicans and E. faecalis might 
promote a commensal interaction with the host, in which virulence attributes are suppressed to 
facilitate colonization (Fig.1) (338). C. albicans ability to colonize the GI tract in a 
nonpathogenic state and switch to a pathogenic state upon disruption of the host immune 
response or microflora has been well documented (4, 8, 11). However, C. albicans is able to 
shape the bacterial microflora during antibiotic recovery. In a murine colonization model C. 
albicans reduced Lactobacillus spp. and promoted E. faecalis colonization after antibiotic 
treatment (366, 367).  These data thus suggest a model in which C. albicans and E. faecalis 
promote each other’s commensalism during nonpathogenic colonization of the 
orogastrointestinal tract, but when the status of the host immune response is disrupted, 
invasive infection might be stimulated.   
We are only beginning to understand the complex interactions amongst the microbiota 
and their varied effects on the human host, but the knowledge is likely to have important 
impacts on the development of novel antimicrobials. In conclusion, I report the identification of 
an anti-fungal, virulence-targeting compound, EntV68, which does not slow the growth of C. 
albicans, even at high concentrations, but can elicit protection in the sub-nanomolar range by 
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inhibiting hyphal morphogenesis. This study provides impetus for further discovery of novel 
antimicrobial therapeutics with virulence-targeting activity. 
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CHAPTER 4:  
 
Post-Translational Processing of EntV influences the inhibition of hyphal 
morphogenesis and biofilm formation of Candida albicans  
 
 
 
 
 
 
 
Portions of this chapter are based on my first author publication. I have received permission to 
reproduce data or text from this article through license number. I have contributed significantly 
to this publication. The article is listed for reference: Graham, C. E., M. R. Cruz, D. A. Garsin, 
and M. C. Lorenz. 2017. Enterococcus faecalis bacteriocin EntV inhibits hyphal 
morphogenesis, biofilm formation, and virulence of Candida albicans. Proc. Natl. Acad. Sci. 
U.S.A. 114: 4507–4512 (303). 
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Introduction: 
 Bacteria use quorum sensing to communicate via accumulation and detection of 
extracellular signaling molecules that enable them to respond to these environmental cues 
based on cell density (368). Gram-positive bacteria QS signaling molecules are peptides that 
are post-translationally processed from propeptides. These peptides bind the extracellular 
receptors on specific transmembrane proteins that trigger specific signal transduction pathways 
(369).  
 The Accessory gene regulator (Agr) system in Staphylococcus Spp. is one of the most-
studied cyclic peptide-mediated QS systems found in Gram-positive bacteria (Novick & 
Geisinger, 2008). The autoinducing peptide (AIP) is produced from the propeptide AgrD that is 
post-translationally processed and secreted by the transmembrane peptidase AgrB. Upon 
accumulation of AIP, the canonical two-component system consisting of the histidine kinase 
(AgrC) and response regulator (Agr A) transduces the signal that results in phosphorylation of 
AgrA (370-374). Phosphorylation activates AgrA, which positively regulated gene expression. 
This type of QS system is widespread among Gram-positive bacteria, cognate gene cluster 
containing these four components have been identified in Enterococcus, Listeria, Clostridium, 
Lactobacillus, and Bacillus spp., suggesting the retention of this type of QS system is important 
for the survival of many Gram-positive bacteria (371, 372, 375, 376).  
 A homolog of the Agr system, the Fsr system in E. faecalis regulates expression of 
pathogenicity-associated genes and is important for virulence in different infection models (197, 
201, 202, 377, 378). The fsr gene cluster contains four genes that encode a histidine kinase 
(FsrA), response regulator (FsrC), transmembrane peptidase (FsrB), and the cyclic signal 
peptide GBAP (FsrD) (376). Phosphorylated FsrA directly regulates the fsr genes, gelE, sprE, 
and entV and indirectly regulates genes involved in autolysis, adhesion, and biofilm formation 
(201, 356, 376, 379). Using microarray transcriptional profiling, Bourgogne et. al. (356) found 
that fsrB influences expression of numerous genes throughout the growth phases of E. 
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faecalis. In addition to the Fsr regulon, gelE, sprE, and entV all contain consensus sequences 
necessary for FsrA binding and expression is dependent on cell density where an increase in 
gene expression is seen in late log phase (356).   
 Here I demonstrate the post-translational modifications of EntV necessary for inhibition 
of C. albicans hyphal morphogenesis and biofilm formation. The mature inhibitory activity was 
3-10 kDa and a synthetic peptide containing the C-terminal 68 amino acids was functional, 
indicating that the EntV protein is post-translationally processed via proteolytic cleavage. I 
show here that recombinant EntV is cleaved in vitro by GelE.  Furthermore, EntV is predicted to 
have a disulfide bond and reduction and alklylation of the supernatant abolished inhibitory 
activity. Finally, characterization of EntV structure and activity provides useful insight for the 
future design of novel antifungal and antibiofilm therapeutics based on EntV inhibitory activity 
against C. albicans. 
 
Results: 
Characterization of E. faecalis supernatant inhibitory activity 
 To characterize the activity of the inhibitor, I used the C. albicans in vitro biofilm model I 
developed using polystyrene as the growth substrate grown in YNBAS (306). Biofilms grown for 
24 hours in the presence of supernatant from E. faecalis had decreased biomass and hyphal 
growth as compared to biofilms grown in medium alone (Fig 4.1.). This inhibitory activity was 
retained in the E. faecalis supernatant fraction between 3 to 10 kDa that had been boiled for 20 
minutes at 100°C (Fig. 4.1), consistent with what was seen in the C. elegans infection model 
(115). In addition, the inhibitory activity was abolished with proteinase K treatment, suggesting 
a small (3 to 10kDa), heat-stable protein is responsible for the inhibitory activity observed in 
both the in vitro biofilm model and the in vivo C. elegans infection model.  
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Figure 4.1:. Characterization of inhibitory activity from E. faecalis Supernatants.  
C. albicans (HWP1p::GFP) biofilms grown at 37°C for 24 hours in YNBAS. Hyphal 
morphogenesis was quantified by measuring GFP fluorescence as a ratio to the OD600. 
Inhibitory activity from E. faecalis supernatant was retained between 3-10 kDa after size 
exclusion centrifugation. A reduction of inhibitory activity was observed in supernatants treated 
with proteinase K and from deletion mutants of fsrB or entV. Experiments were repeated at 
least three times and statistically significant differences relative to treatment with the WT 
supernatant were calculated using a one-way ANOVA, and are indicated by asterisks (**, 
p<0.006; *, p<0.01). 
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Post-translational processing of EntV  
 As discussed previously (Chapter 1), the inhibitory activity was lost with disruption of the 
Fsr system and deletion of entV (Fig. 3.3A). Furthermore, deletion of gelE or sprE resulted in 
decreased inhibitory activity and a double deletion of gelE and sprE further decreased inhibitory 
activity, indicating that GelE and SprE are necessary for maximum inhibitory activity. According 
to the entV gene sequence, EntV is slightly larger than the inhibitory factor characterization 
based on size exclusion centrifugation (Fig. 4.2). Proteolytic processing of EntV is a plausible 
explanation for this size discrepancy. Since GelE and SprE cleave E. faecalis surface and 
secreted proteins, they are candidates for processing EntV (321, 379). 
 To test the hypothesis that GelE and/or SprE proteolytically process EntV, in silico and 
in vitro tests were performed. A member of the M4 family of proteases thermolysin, a homolog 
of GelE from Bacillus thermoproteolyticus, preferentially cleaves sites with position P1' that 
have bulky and aromatic residues (Ile, Leu, Val, Ala, Met,  Phe) and aromatic sites in position 
P1 [392]. Glutamyl endopeptidases V8 from Staphylococcus aureus is a homolog of serine 
protease (SprE) from E. faecalis and preferentially cleaves at Glu in position P1, Pro/Val or Phe 
in position P2, Ala/Val in position P3, and Asp in position P4 (380). Thus, proteolytic cleavage 
of EntV by these homologous proteases was examined in silico using PeptideCutter (ExPasy) 
[394].  
 EntV contains two cysteines that form a putative disulfide bond that is necessary for 
bactericidal activity (358). To examine the role of the disulfide bond for activity against C. 
albicans, E. faecalis supernatant was reduced followed by alkylation to permanently reduce any 
cysteine in the supernatant. As illustrated in Figure 4.3A, a reduction in the inhibitory activity of 
WT supernatant was observed after reductive-alkylation, suggesting that the disulfide bond is 
also necessary for the inhibitory activity against C. albicans. Disulfide bond formation in Gram-
positive bacteria has been understudied and is not fully understood. On the other hand disulfide 
bond formation in Gram-negative bacteria has been extensively studied. Since Gram-positive 
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Figure 4.2: The E. faecalis Fsr system is involved in regulating the inhibitory activity. 
The Fsr two component quorum-sensing system from E. faecalis regulates expression of EntV 
and secreted proteases (GelE and SprE) (356). C. albicans (HWP1p::GFP) biofilms grown at 
37°C for 24 hours in YNBAS. Hyphal morphogenesis was quantified by measuring GFP 
fluorescence as a ratio to the OD600. Disruption of gelE and/or sprE decreased inhibitory 
activity. Experiments were repeated at least three times and statistically significant differences 
relative to treatment with the WT supernatant were calculated using a one-way ANOVA, and 
are indicated by asterisks (**, p<0.009). 
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bacteria lack traditional periplasmic spaces it has been thought that these disulfide bonds are 
formed spontaneously upon secretion or that many Firmicutes secrete few, if any, proteins that 
have disulfide bonds (381). However, recent studies have demonstrated the importance of 
disulfide bond formation by thiol-disulfide oxidoreductases (DsbA-like proteins) in Gram-
positive actinobacteria (382). Interesting, disruption of dsbA by transposon mutagenesis also 
resulted in reduced inhibitory activity (Fig. 4.3A). Taken together these results demonstrate that 
protein oxidation is necessary for maximum inhibitory activity, which suggests that proper 
formation of the disulfide bond is necessary for EntV efficacy. 
 Disulfide bridges stabilize the formation of β-strands and α-helices, can control 
substrate accessibility, and protect proteins from damage. Therefore, only cleavage sites 
outside of the disulfide bonds are shown (383-385). As illustrated in Figure 4.3B, GelE cleaves 
at A68 and SprE cleaves at residues further toward the N-terminus, which corresponds with 
previous MS/MS analysis and N-terminal degradation sequencing of EntV from WT E. faecalis 
(245). Thus, these data suggest that GelE is important for cleavage of the EntV propeptide to 
produce the active bacteriocin. Additionally, GelE also cleaves the C-terminus of EntV in silico 
resulting in production of a 65 amino acid peptide of 6.9 kDa in size (Fig. 4.3B). 
 To investigate further the proteolytic processing of EntV by GelE, recombinant EntV136 
(136 amino acid propeptide) expressed and purified from E. coli (BL21-DE3) was incubated 
with increasing concentrations (1.5, 4.5, 15, and 30 μg/ml) of purified GelE from E. faecalis 
(321). I observed increased amounts of lower molecular weight EntV (~7KDa) with increased 
concentrations of GelE (Fig. 4.4), indicating proteolytic processing of EntV by GelE. This 
supports previous reports that demonstrate the propeptide (136 amino acids, ~15kDa) is further 
modified by the extracellular gelatinase into the active bacteriocin of 68-amino acid (7kDa) 
peptide that has been shown to be active against bacteria (245). As discussed in Chapter 3, I  
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Figure 4.3: Protein oxidation is important for inhibitory activity.  
(A) C. albicans (HWP1p::GFP) biofilms grown at 37°C for 24 hours in YNBAS. Hyphal 
morphogenesis was quantified by measuring GFP fluorescence as a ratio to the OD600. 
Reductive-Alkylation decreased inhibitory activity of WT E. faecalis supernatant. Disruption of 
dsbA (predicted dithiol-disulfide isomerase) by transposon mutagenesis also decreased 
inhibitory activity. Experiments were repeated at least three times and statistically significant 
differences relative to treatment with the WT supernatant were calculated using a one-way 
ANOVA, and are indicated by asterisks (**, p<0.01, ***p<0.001). (B) In silico digestion of EntV 
by GelE homolog thermolysin (T) and SprE homolog glutamylpeptidase (G) using 
PeptideCutter (ExPASy) (242). 
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Figure 4.4:. EntV is proteolystically processed by E. faecalis gelatinase.  
GelE cleavage of rEntV136 was analyzed by SDS-PAGE. Increasing amounts of purified GelE 
was incubated with 30μg/ml rEntV136 N-terminally tagged with hexa-His for 1hr and the 
reactions terminated by addition of SDS-PAGE sample buffer and boiling. Proteins were 
stained with SyproRuby (Lonza) and visualized using a 300 nm UV transilluminator. Increased 
concentrations of GelE resulted in production of smaller molecular weight products (>10kDa).  
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demonstrated this processed peptide of 68-amino acid inhibited hyphal morphogenesis, biofilm 
formation, and virulence of C.albicans. 
Classification and structure of E. faecalis bacteriocin EntV 
 EntV belongs to the class IIIb bacteriocins, which are the larger (>10kDa), non-lytic 
bacteriocins produced by Gram-positive bacteria [400]. To date only five bacteriocin have been 
identified and characterized in this class, dysgalacticin (DysA, Streptococcus dysgalactiae 
subsp. equisimilisI), SA-M57 (Streptococcus pyogenes M-type 57), EntV (E. faecalis), and 
YpkK (Corynebacterium jeikeium) (243, 358, 386). Each of these proteins have conserved 
secondary structures: (1) unstructured N-terminus, (2) helix-loop-helix motif at the C-terminus, 
and (3) two cysteine residues that form a putative disulfide bond (242, 243, 358, 386) (Fig. 4.5A 
and B). In Addition, these class IIIb bacteriocins have a non-lytic mode of action against similar 
Gram-positive bacteria and only EntV has been test against fungi (245, 358).  
 I hypothesized that these other bacteriocins similar to EntV are also proteolytically 
cleaved by proteases of the M4 family, homologs of thermolysin, aurolysin and gelatinase 
(GelE). As seen in Table 4.1, M4 family proteases have been identified in these other bacterial 
species and proteolytic cleavage by thermolysin was observed in silico (387). Furthermore, all 
of the class IIIb bacteriocins gain a greater positive charge that is characteristic of efficacious 
antimicrobial peptides (Table 4.1, ProtParam) [403]. Using the protein structure of dysgalacticin 
in consort with the secondary structure consensus (PROMALS3D) of the class IIIb bacteriocins 
the predicted tertiary structure was assembled (I-Tasser) (242, 388). Collectively, these results 
suggest that the class IIIb bacteriocins are post-translational processing into small (<10kDa), 
positively charged, amphipathic bacteriocins.  
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Figure 4.5: Comparative primary and secondary structures of class IIIb bacteriocins after 
proteolytic processing.  
The first amino acid was determined by in silico digestion of each bacteriocin with M4 family 
protease thermolysin (PeptideCutter, ExPASy). All bacteriocins have conserved cysteines 
involved in disulfide bond formation. (A) ClustalW alignment of EntV, SA-M57, DysA, and YpkK 
bacteriocins (242, 358). * indicates conserved amino acids; : indicates amino acids with 
strongly similar function; and . indicates amino acids with weakly similar function (Network 
Protein Sequence Analysis, NPS) (358). (B) Multiple alignment with predicted secondary 
structure of EntV, SA-M57, DysA, and YpkK bacteriocins (PROMALS3D) (389). The 
conservation indices for positions with a conservation index above 4 are shown at the top of the 
alignment block. Sequences are colored according to predicted secondary structures (red: 
alpha-helix). Just below the alignment sequence is the consensus amino acid symbols: 
conserved amino acids are in bold and uppercase letters; aliphatic (I, V, L): l; aromatic (Y, H, 
W, F): @; hydrophobic (W, F, Y, M, L, I, V, A, C, T, H): h; polar residues (D, E, H, K, N, Q, R, S, 
T): p; tiny (A, G, C, S): t; small (A, G, C, S, V, N, D, T, P): s; bulky residues (E, F, I, K, L, M, Q, 
R, W, Y): b. Below the consensus amino acid symbols are the consensus predicted secondary 
structure symbols (alpha-helix: h). 
 
EntV          LGSCVANKIKDEFFAMISISAIVKAAQKKAWKELAVTVLRFAKANGLKTNAIIVAGQLALWAVQC---- 
SA-M57        LGNCMANKIKDELLAMISVGTIIKYAQKKAWKELAKIVIKYVAKAGVKTNAALIAGQLAIWGLQC---- 
YpkK          L-TCIKGKASDDIKSVFDVNVVAAAIGQKDYAKAAKEAVKYLAKQGVKRNAAALAGMFAYWGWQCRGSW 
DysA          IQRCLEEAWGYAIS-LVTLKGIINLFKAGKFEAAAAKLAS--ATAG---RIAGMAALFAFVA-TC---- 
              :  *:       :  :. :  :        :   *          *   .   :*. :*  .  *     
Consensus     lgsCvankikdei amisv aiikaaqkkawke Ak vlkyvakaGvktnaa vAgq A wavqC     
 
 
 
 
 
 
Conservation:          9   5  5    5     5      9  5 595 5           59   995 9 55 55      
DysA             1  IQRCLEEAWGYAISLVTLKGIINLFK AGKFEAAAAKLASA---------TAGRIAGMAALFAFVATC--   58  
YpkK             1  -LTCIKGKASDDIKSVFDVNVVAAAIGQKDYAKAAKEAVKYLAK QGVKRNAAALAGMFAYWGWQCRGSW   68  
SA-M57           1  LGNCMANKIKDELLAMISVGTIIKYAQKKAWKELAKIVIKYVAK AGVKTNAALIAGQLAIWGLQC----   65  
EntV             1  LGSCVANKIKDEFFAMISISAIVKAAQKKAWKELAVTVLRFAKA NGLKTNAIIVAGQLALWAVQC----   65  
Consensus aa:       ..pCh...h...h..hh..shl..h...K.b..hA..h...........sA..lAGbhAh@th.t....  
Consensus ss:         hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh     hhhhhhhhhhhhhhhhh 
 
A 
B 
 
EntV          LGSCVANKIKDEFFAMISISAIVKAAQKKAWKELAVTVLRFAKANGLKTNAIIVAGQLALWAVQC---- 
SA-M57        LGNCMANKIKDELLAMISVGTIIKYAQKKAWKELAKIVIKYVAKAGVKTNAALIAGQLAIWGLQC---- 
YpkK    L-TCIKGKASDDIKSV DVNVVAA GQKDYAKA KEAVKYLAKQGVKRNAAA AGMFAYWGWQCRGS  
DysA    IQRCLEE WGYAIS- VTLKGIINLFKAGKFEAA A LAS--ATAG---RIAGMAALF FVA-TC---- 
         :  *:       :  :. :  :        :   *          *   .   :*. :*  .  *     
Consensus     lgsCvankikdei amisv aiikaaqkkawke Ak vlkyvakaGvktnaa vAgq A wavqC     
 
 
 
 
 
 
Conservation:          9   5  5    5     5      9  5 595 5           59   995 9 55 55      
DysA             1  IQRCLEEAWGYAISLVTLKGIINLFK AGKFEAAAAKLASA---------TAGRIAGMAALFAFVATC--   58  
YpkK             1  -LTCIKGKASDDIKSVFDVNVVAAAIGQKDYAKAAKEAVKYLAK QGVKRNAAALAGMFAYWGWQCRGSW   68  
SA-M57           1 LGNCMANKIKDELLAMISVGTIIKYAQKKAWKELAKIVIKYVAK AGVKTNAALIAGQLAIWGLQC----  65  
EntV             1  LGSCVANKIKDEFFAMISISAIVKAAQKKAWKELAVTVLRFAKA NGLKTNAIIVAGQLALWAVQC----   65  
Consensus aa:       ..pCh...h...h..hh..shl..h...K.b..hA..h...........sA..lAGbhAh@th.t....  
Consensus ss:         hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh     hhhhhhhhhhhhhhhhh 
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Table 4.1. Computation of physical and chemical properties of class IIIb bacteriocins. 
 Based on the sequence analysis of the propeptide and proteolytically processed active peptide 
the size and theoretical pI was calculated using ProtPram (ExPASy). Identification of M4 family 
proteases was preformed using the NCBI gene database. 
 
 
 
 
 
 
 
  
Species Bacteriocin Gene M4 Family Protease 
E. faecalis Enterococcin V entV Gelatinase (gelE) 
S. dysgalactiae  Dysgalacticin dysA Oligoendopeptidase F (pepF) 
S. pyogenes  SA-M57 scnM57 Peptidase F (pepF) 
C. jeikeium  Corynicin JK ypkK Zn-dependent metalloprotease (JKRS06030) 
Bacteriocin Propeptide Size 
(kDa) 
Theoretical pI Active Peptide Size 
(kDa) 
Theoretical pI 
Enterococcin V 14 (136 a.a.) 4.87 6.9 (65 a.a.) 9.84 
Dysgalacticin 16.8 (152 a.a.) 4.77 7.0 (65 a.a.) 9.75 
SA-M57 14.4 (137 a.a.) 5.40 7.3 (68 a.a.) 9.60 
Corynicin JK 21.5 (192 a.a.) 4.46 6.0 (58 a.a.) 9.24 
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Discussion: 
 Important for competition and commensal growth in the GI tract of the host, post-
translational processing of bacteriocins is common for efficient production of antimicrobial 
peptide against bacteria and fungi (390).  Here I demonstrate that EntV is processed in an Fsr-
dependent manner into a mature form of 68 amino acids that has activity at nanomolar or lower 
concentrations in most of our assays, demonstrating that it is highly efficacious.   
EntV is a bacteriocin that belongs to the class IIIb bacteriocins, which are the larger 
(>10kDA) bacteriocins (391). The structure of the mature form of EntV is predicted in silico to 
consist of two helical elements, separated by a flexible loop region. The conserved cysteines 
located immediately before and after these two helices are thought to form a disulfide bond 
(392, 393). The immature form contains an additional N-terminal segment predicted to be 
unstructured (245), which is removed by GelE to form the mature and active form of the peptide 
(245). While many bacteriocins encode an immunity protein, Dundar et al. could find no 
evidence of one, and E. faecalis appears to be intrinsically resistant (358). The bacteriocidal 
activity of EntV against sensitive species is not due to lysis, and the mechanism remains 
enigmatic (242).  
The class IIIb bacteriocins that have been identified to date have a similar predicted 
secondary, though are not well conserved at the amino acid level. Considering the structure 
similarity and conserved cysteines necessary for activity and in silico cleavege, it is plausible 
that these other class IIIb bacteriocins, like EntV are also post-translational modified resulting in 
production of a smaller (<10kDA) highly active positively charged antimicrobial peptide. Thus, 
characterization and classification of these bacteriocins may need revision (242, 243, 358, 
394). EntV-like bacteriocins have been identified in multiple host-associated bacteria 
suggesting these bacteriocins are important for both pathogenic and commensal association 
with the host (303). Furthermore, given the physiochemical similarities of these bacteriocins it is 
possible that they have overlapping target spectra. This remains to be further tested and 
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suggests that these bacteriocins may play an important role in bacterial-fungal interactions in 
other Gram-positive bacteria.  
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CHAPTER 5: 
 
Assessment of EntV mechanism of action against C. albicans 
 
 
 
 
 
 
 
Portions of this chapter are based on my first author publication. I have received permission to 
reproduce data or text from this article through license number. I have contributed significantly 
to this publication. The article is listed for reference: Graham, C. E., M. R. Cruz, D. A. Garsin, 
and M. C. Lorenz. 2017. Enterococcus faecalis bacteriocin EntV inhibits hyphal 
morphogenesis, biofilm formation, and virulence of Candida albicans. Proc. Natl. Acad. Sci. 
U.S.A. 114: 4507–4512 (303). 
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Introduction: 
 C. albicans biofilms are complex, structured communities that form on biotic and abiotic 
surfaces and are a growing concern in the clinical setting. One of the leading opportunistic 
fungal pathogens, C. albicans biofilms are often difficult to eradicate and can lead to more 
severe systemic infection if left untreated. Comprised of both yeast and hyphal cells C. albicans 
biofilms form via a highly regulated process that begins with adhesion, followed by initiation and 
formation of hyphal cells, then maturation, and ultimately dispersion (Fig. 1.1) (41).  
 Adherence is the first essential stage in C. albicans biofilms development and is a 
highly regulated process. Factors such as cell surface composition, extracellular matrix 
production, adhesins and other cell surface proteins are all coordinated during attachment to a 
substrate. Finkel et al. (395), identified 30 transcriptional regulators that are important for 
adherence during biofilm development, which regulate the expression of 37 surface-associated 
genes among other genes. Furthermore, a functional relationship between cell wall stress 
responses and regulation of adherence was identified recently. Transcriptional repression of 
ARC18, a member of the Arp2/3 complex important for regulation of endocytosis and the actin 
cytoskeleton, resulted in reduced adhesion and biofilm formation (395). Additionally, cell 
surface hydrophobicity and exposure of cell wall chitin and β-glucans was increased with 
depletion of the Arp2/3 complex leading to impaired cell wall integrity and activation of Rho1-
mediated cell wall stress responses (50, 396-398).  
 C. albicans cell wall proteins are essential for maintaining cell wall integrity, adherence, 
enzymatic functions, biofilm development, and morphological transition. In C. albicans, a MAPK 
network regulates responses to environmental stresses such as changes in temperature, 
osmolarity, ionic stress, cell wall stress, and oxidative stress. Three interconnected MAPK 
pathways, Hog1, Mkc1 and Cek1, regulate this core transcriptional response to environmental 
stress (50, 398-400). Different membrane sensors sense environmental stress signals; the 
signals are transduced via the MAPK pathways, resulting in cooperative phosphorylation of 
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Hog1 and Cek1 followed by phosphorylation of Mkc1. Collectively, this results in generation of 
a core transcriptional stress response (3). While components of the core stress responses have 
been identified many of the sensors have not been identified or remain uncharacterized in C. 
albicans. 
 I hypothesize that EntV is eliciting a cell surface stress that disrupts cell surface 
proteins, adhesion and thus biofilm formation and hyphal morphogenesis. Here I identify C. 
albicans genes that when deleted decrease sensitivity to E. faecalis inhibitory activity during 
biofilm development. Deletion in genes involved in regulation of hyphal morphogenesis, cell 
wall stress, and cell wall architecture were identified. Furthermore, assessment of sEntV68 
localization by fluorescence microscopy in yeast and hyphal cells demonstrated surface 
association in all cell types. Although sEntV68 inhibits hyphal morphogenesis, biofilm formation 
and virulence of C. albicans, sEntV68 did not kill C. albicans, nor inhibit its growth, even at high 
concentrations. sEntV68 inhibits hyphal morphogenesis and biofilm formation in clinical isolates 
of C. albicans, as well as other pathogenic Candida spp. EntV68, or similar compounds, may 
offer a viable therapeutic alternative. Understanding the mechanism of action is important for 
development and use of EntV68 based therapeutics. Identification of genes dysregulated by E. 
faecalis will provide insight into possible gene targets for development of therapeutic strategies 
that target hyphal morphogenesis and biofilm development (303). 
 
Results: 
Role of hyphal morphogenesis and surface stress response  
 E. faecalis secretes an inhibitor of C. albicans virulence and biofilm formation that I 
have identified as the bacteriocin EntV (23, 42, 49). Hyphal morphogenesis was reduced in 
both in vitro and in vivo assays, suggesting that the E. faecalis mediated inhibition C. albicans 
is due to dysregulation of hyphal morphogenesis pathways. Thus, I hypothesized that E. 
faecalis dysregulates hyphal-specific genes in C. albicans that are important for hyphal 
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morphogenesis and thus biofilm development. As mentioned previously, hyphal morphogenesis 
and biofilm formation of C.  albicans are interconnected and regulated by the Ras1-cAMP-PKA 
signal pathway (401, 402).  This is important when considering the mechanism of action of E. 
faecalis-mediated inhibition of hyphal morphogenesis and biofilm formation. 
 To understand the mechanism of action I assessed C. albicans mutant libraries of 
transcription factors and cell wall proteins (303) for decreased sensitivity to E. faecalis 
supernatant. Biofilms were grown as described above using the resazurin redox assay to 
quantify biofilm biomass (401). Resistance to WT E. faecalis supernatant was determined by 
comparing supernatant treated cells to media treated controls. Homozygous deletion mutants 
in non-essential transcription factors and cell wall proteins that were resistant to E. faecalis 
supernatant are listed in Table 5.1. Theses homozygous deletion mutants have known 
functions in hyphal morphogenesis, cell wall biogenesis, mating, cell cycle and unknown 
function. 
  24 Transcription factor mutants were identified that were less sensitive to E. faecalis 
supernatant (Table 5.1) (401, 403, 404). Some of the transcription factor mutants identified are 
involved in negatively regulating hyphal morphogenesis (NRG1, SSN6, RAP1), deletion of 
these genes results in a hyperfilamentous phenotype (400, 405). Transcription factor mutants 
identified involved in cell wall biogenesis genes and that are linked to the cell wall integrity 
(CWI) or Hog1 stress response signal cascades (CAS5, SKO1, FCR1, ORF19.2476) were also 
identified (398, 406, 407). 15 cell wall protein deletion mutants were identified that decreased 
sensitivity to E. faecalis supernatant (Table 2.2). Moreover, cell wall protein deletion mutants 
identified are also linked to hyphal morphogenesis (PDE2) and surface stress response 
(WSC1, WSC2, WSC4, PGA26, CCW14, ECM4) (107). Taken together these data suggest E. 
faecalis supernatant is triggering an adaptive stress response in C. albicans that leads to 
repression of morphogenesis (49). 
 The Ras1-cAMP-PKA signal pathway regulates hyphal morphogenesis during biofilm 
development (48). Therefore, inhibition of C. albicans biofilm formation would likely involve  
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Table 5.1: Homozygous deletion mutants in non-essential transcription factors resistant 
to E. faecalis supernatant.  
C. albicans homozygous deletion mutants were screened for resistance to E. faecalis 
supernatant biofilm inhibition. Biofilms were grown in YNBAS for 24 hours and biofilm biomass 
was quantified using the resazurin redox assay comparing biofilms grown in the presence or 
absence of WT E. faecalis supernatant.  
 
 
 
 
  
Gene Systematic Name 
S. cerevisiae 
Ortholog  
Function 
HMS1 C5_00670C_A  HMS1 Filamentation 
GLN3 C5_04280C_A GLN3 Nitrogen Stress, Filamentation 
C5_04410C_A C5_04410C_A AZF1 Unknown (Cell Cycle in S. cerevisiae) 
GRF10 C5_05080W_A  PHO2 Filamentation, Adenine Biosynthesis 
ZCF21 C4_00760W_A LYS14 Cell Wall Biogensis and Stress, Pathogenesis 
CAS5 C4_01190W_A MOT3 Cell Wall Biogensis and Stress, Filamentation, Pathogenesis 
CWT1 CR_05530C_A  RDS2 Cell Wall Biogensis and Stress, Nitrogen Stress, Filamentation 
MBP1 C3_04110C_A MBP1 Cell Cycle 
TRY4 C3_05050W_A ADR1 Cell Adhesion 
WOR2 C3_05170W_A UME6 Filamentation, Phenotypic Switching 
C2_05640W_A  C2_05640W_A  BAS1 Filamentation 
STP4 C2_03220C_A STP3 Filamentation 
SKO1 C1_03770W_A SKO1 Filamentation, Cell Wall Stress, Oxidative Stress, Cell 
CRZ2 CR_07060C_A CRZ1 Cell Adhesion, pH Response 
C1_05750C_A C1_05750C_A ECM5 Oxidative Stress 
MSN4 C1_08940C_A MSN2 Oxidative Stress 
SSN6 C3_07020W_A CYC8 Filamentation, Pathogenesis 
FCR1 C3_06850W_A CAT8 Filamentation 
NRG1 C7_04230W_A NRG2 Filamentation 
RIM101 C1_14340C_A RIM101 Filamentation, pH Response 
AAF1 C3_06470W_A - Filamentation, Cell Adhesion 
CPH2 C6_00280W_A HMS1 Filamentation 
KAR4 CR_02330C_A  KAR4 Mating  
RAP1 C2_10080W_A  RAP1 Filamentation 
Gene Systematic Name 
S. cerevisiae 
Ortholog  
Function 
PGA26 C1_05760C_A - Filamentation, Cell Wall Stress 
PGA7 C4_00120W_A - Biofilm ECM, Pathogenesis 
PDE2 C1_02840W_A PDE2 Filamentation, Adhesion, Cell Wall Organization 
WSC1 C3_04250W_A  WSC2 Cell Wall Stress, Cell Wall Organization 
WSC2 C6_02670C_A  WSC2 Cell Wall Stress 
WSC4 C1_14360C_A  WSC4 Cell Wall Stress 
MNN4-4 C6_02830W_A MNN4 Cell Wall Biogensis and Stress 
MNN10 C4_00310C_A Mnn10 Cell Wall Biogensis 
MP65 C2_10030C_A SCW10 Cell Wall Biogensis and Stress, Filamentation, Adhesion, Pathogensis 
CCW14 C5_01010W_A - Cell Wall Stress 
VTI1 C3_03400C_A VTI1 Golgi to Vacuole Transport  
ECM4 CR_02130W_A ECM4 Core Stress Response, Filamentation 
ECM21 C1_10180C_A  ECM21 Endocytosis 
ECM25 C1_13310W_A ECM25 Filamentation 
SAP98 C2_03680W_A PEP4 Phenotypic Switching 
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Table 5.2: Homozygous deletion mutants in cell wall proteins resistant to E. faecalis 
supernatant.  
C. albicans homozygous deletion mutants were screened for resistance to E. faecalis 
supernatant biofilm inhibition. Biofilms were grown in YNBAS for 24 hours and biofilm biomass 
was quantified using the resazurin redox assay to compare biofilms grown in the presence or 
absence of WT E. faecalis supernatant.  
 
Gene Systematic Name 
S. cerevisiae 
Ortholog  
Function 
HMS1 C5_00670C_A  HMS1 Filamentation 
GLN3 C5_04280C_A GLN3 Nitrogen Stress, Filamentation 
C5_04410C_A C5_04410C_A AZF1 Unknown (Cell Cycle in S. cerevisiae) 
GRF10 C5_05080W_A  PHO2 Filamentation, Adenine Biosynthesis 
ZCF21 C4_00760W_A LYS14 Cell Wall Biogensis and Stress, Pathogenesis 
CAS5 C4_01190W_A MOT3 Cell Wall Biogensis and Stress, Filamentation, Pathogenesis 
CWT1 CR_05530C_A  RDS2 Cell Wall Biogensis and Stress, Nitrogen Stress, Filamentation 
MBP1 C3_04110C_A MBP1 Cell Cycle 
TRY4 C3_05050W_A ADR1 Cell Adhesion 
WOR2 C3_05170W_A UME6 Filamentation, Phenotypic Switching 
C2_05640W_A  C2_05640W_A  BAS1 Filamentation 
STP4 C2_03220C_A STP3 Filamentation 
SKO1 C1_03770W_A SKO1 Filamentation, Cell Wall Stress, Oxidative Stress, Cell 
CRZ2 CR_07060C_A CRZ1 Cell Adhesion, pH Response 
C1_05750C_A C1_05750C_A ECM5 Oxidative Stress 
MSN4 C1_08940C_A MSN2 Oxidative Stress 
SSN6 C3_07020W_A CYC8 Filamentation, Pathogenesis 
FCR1 C3_06850W_A CAT8 Filamentation 
NRG1 C7_04230W_A NRG2 Filamentation 
RIM101 C1_14340C_A RIM101 Filamentation, pH Response 
AAF1 C3_06470W_A - Filamentation, Cell Adhesion 
CPH2 C6_00280W_A HMS1 Filamentation 
KAR4 CR_02330C_A  KAR4 Mating  
RAP1 C2_10080W_A  RAP1 Filamentation 
Gene Systematic Name 
S. cerevisiae 
Ortholog  
Function 
PGA26 C1_05760C_A - Filamentation, Cell Wall Stress 
PGA7 C4_00120W_A - Biofilm ECM, Pathogenesis 
PDE2 C1_02840W_A PDE2 Filamentation, Adhesion, Cell Wall Organization 
WSC1 C3_04250W_A  WSC2 Cell Wall Stress, Cell Wall Organization 
WSC2 C6_02670C_A  WSC2 Cell Wall Stress 
WSC4 C1_14360C_A  WSC4 Cell Wall Stress 
MNN4-4 C6_02830W_A MNN4 Cell Wall Biogensis and Stress 
MNN10 C4_00310C_A Mnn10 Cell Wall Biogensis 
MP65 C2_10030C_A SCW10 Cell Wall Biogensis and Stress, Filamentation, Adhesion, Pathogensis 
CCW14 C5_01010W_A - Cell Wall Stress 
VTI1 C3_03400C_A VTI1 Golgi to Vacuole Transport  
ECM4 CR_02130W_A ECM4 Core Stress Response, Filamentation 
ECM21 C1_10180C_A  ECM21 Endocytosis 
ECM25 C1_13310W_A ECM25 Filamentation 
SAP98 C2_03680W_A PEP4 Phenotypic Switching 
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perturbation of this signal cascade (408). Interestingly, deletion of negative regulators of the 
signal pathway, NRG1 and PDE1, conferred resistance to E. faecalis, demonstrating the 
importance of the Ras1-cAMP-PKA signal pathway regulation of hyphal morphogenesis in 
response to E. faecalis (Fig 5.1A). This suggests that E. faecalis-mediated inhibition requires 
repressors of hyphal morphogenesis that are most likely induced during inhibition. Nrg1 is 
essential for the hyphal to yeast transition during the dispersal stage of biofilm development 
and negatively regulates the biofilm transcriptional network (155). Pde2 is a high affinity cyclic 
nucleotide phosphodiesterase that moderates signaling by cAMP in the Ras1-cAMP-PKA 
signal pathway (50, 397, 400). 
 The stress response MAPK network consists of three terminal MAPKs, Hog1, Mkc1 and 
Cek1, that are phosphorylated as a result of membrane sensors signaling in responses to 
environmental stress, such as surface stress (48, 399). Deletion of transcription factors 
regulated by the MAPK network, CAS5, SKO1, and FCR1, conferred resistance to E. faecalis, 
demonstrating a possible role of the MAPK pathway during inhibition hyphal morphogenesis by 
E. faecalis (Fig 5.1B). Furthermore, deletion of the poorly understood cell wall integrity sensors, 
WSC1, WSC2, and WSC4, decreased sensitivity to E. faecalis supernatant (Fig. 5.1B). At the 
center of the MAPK network is Hog1-MAPK, which at basal concentrations represses Cek1 and 
controls phosphorylation of Mkc1 (5, 409). Phosphorylated Hog1 acts a repressor of hyphal 
morphogenesis independently of Efg1 and Cph1 by regulating Sko1-Ssn6-Tup1 mediated 
repression. Thus, I hypothesized that the Hog1-MAPK stress response pathway is activated in 
C. albicans due to E. faecalis-mediated perturbation of the cell wall and membrane. Deletion of 
HOG1 resulted in decreased sensitivity to E. faecalis supernatant (Fig 5.2). Taken together 
these results suggest that the stress response MAPK network is activated in response to E. 
faecalis-mediated stress. 
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Figure 5.1: Deletion of hyphal morphogenesis and cell wall stress genes confers 
resistance to E. faecalis supernatant.  
C. albicans homozygous deletion mutants were screened for resistance to E. faecalis 
supernatant biofilm inhibition. Biofilm biomass was quantified using the resazurin redox assay 
comparing no treatment biofilms (blue) to supernatant treated biofilms (orange). (A) Deletion of 
genes involved in repression of the Ras1-cAMP pathway resulted in decreased sensitivity to E. 
faecalis supernatant. (B) Deletion of genes involved in cell wall stress resulted in decreased 
sensitivity to E. faecalis supernatant. Statistically significant differences relative to treatment 
with the WT supernatant were calculated using a Student’s t-test, and are indicated by 
asterisks (**, p<0.007; *, p<0.04). 
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Figure 5.2: Deletion of the central stress response MAPK, HOG1, decreased C. albicans 
sensitivity to E. faecalis supernatant.  
Treatment with E. faecalis WT supernatant did not decrease biofilm biomass of a HOG1 
homozygous deletion mutant and complementation of the WT HOG1 restored sensitivity. was 
resistance to E. faecalis supernatant biofilm inhibition. Biofilm biomass was quantified using the 
resazurin redox assay comparing no treatment biofilms (blue) to supernatant treated biofilms 
(orange). Statistically significant differences relative to treatment with the WT supernatant were 
calculated using a Student’s t-test, and are indicated by asterisks (**, p<0.006; *, p<0.03). 
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Host relevant environmental stresses impact on EntV activity 
Functional stress response is important for C. albicans survival by initiating adaptation 
to changes in environmental conditions (401). Induction of MAPK stress response pathways  
has been observed in C. albicans in response to various external factors that lead to inhibition 
of hyphal morphogenesis and biofilm formation. Thus, I considered whether sEntV might 
synergize with host-relevant stresses, including oxidative, nitrosative, cell wall, and cell 
membrane stresses. The addition of sEntV68 did not affect susceptibility to any of these 
stresses, reinforcing the idea that it has a novel mechanism of action (Fig 5.3). These results 
do not correspond with our previous observations in the in vitro biofilm model. There are some 
plausible explanations: (1) there is no stress response, (2) the stress response is specific to 
biofilm growth (e.g. adhesion), and/or (3) the stress growth conditions impedes the activity of 
EntV68 (e.g. cell surface remodeling). This remains to be fully elucidated and will need to be 
further examined. 
 
EntV activity on C. albicans in different growth conditions  
 To better understand the sEntV68 mechanism of action, I considered whether EntV 
might inhibit biofilm formation as a result of a general inhibition of fungal growth. To address 
this, I grew C. albicans in the presence of increasing concentrations of sEntV68 and found no 
reduction in growth as high as 10 µM, 30,000-fold higher than the in vitro biofilm inhibitory 
concentration (Fig 5.4). Although sEntV68 was very effective at inhibiting biofilm formation in 
artificial saliva medium (YNBAS), I questioned the efficacy of sEntV68 in stronger hyphal 
inducing conditions. As illustrated in Figure 5.5, sEntV68 is highly active in a variety of media 
conditions, including fetal bovine serum (FBS), which is a robust hyphal inducer (Fig. 5.5) 
 
Role of cell wall composition in response to E. faecalis mediated inhibition 
 While many of the genes identified in the homozygous deletion mutants screen have 
hyper-filamentous phenotypes, deletion of ZCF21 conferred resistance to E. faecalis  
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Figure 5.3: Impact of host relevant stresses on sEntV68 activity.  
C. albicans (SC5314) was grown for 15 hours in YPD at 30° C with sEntV68 (100 nM) in 
different stress conditions: cell wall stress (A) calcofluor white (100 μg/ml) and (B) SDS (10%); 
cell membrane stress (C) sorbitol (1 M) and (D) Sodium Chloride (1 M); oxidative stress (E) 
hydrogen peroxide (5 mM) and (F) menadione (100 μM)  in a 96 well plate. OD600 was 
measured every two minutes in a microplate reader.  
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Figure 5.4: sEntV68 activity on planktonic C. albicans yeast cells.  
C. albicans was grown at 30°C in YPD for 15 hours with shaking in a 96 well plate with 
increasing concentrations of sEntV68. Growth of was quantified by measuring absorbance 
(OD600) every two minutes in a microplate reader (BioTek).  
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Figure 5.5:. sEntV68 inhibitory activity in different media types.  
C. albicans (HWP1p::GFP) biofilms grown for 24 hours at 37°C in YNBAS, RPMI, Spider, or 
YPD with 10% fetal bovine serum with 0.01% DMSO (blue) or 100 nM sEntV (orange). Hyphal 
morphogenesis was quantified by measuring GFP fluorescence as a ratio to the OD600 for three 
separate experiments and statically significant differences were calculated using a Student’s t-
test (*p<0.01). 
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supernatant in a hyper-filamentous independent manner (Fig. 5.6, Table 2.1) (9). Zcf21p 
negatively regulates expression of genes that encode cell surface proteins important for C. 
albicans virulence (410). Bohm et al. (280), found that ZCF21 regulates cell wall structure and  
composition, including proteins and carbohydrates in the cell wall. Furthermore, the 
homozygous ZCF21 deletion mutant had decreased sensitivity to sEnV68, suggesting that 
deletion of ZCF21 causes changes in the cell wall structure and composition preventing 
sEntV68 inhibition. 
 
EntV localization in C. albicans 
 Analysis of the primary and predicted secondary structure (Chapter 4) indicate EntV68 
has similar physicochemical properties to human antimicrobial peptides active against C. 
albicans that elicit a surface stress response that is initiated via interactions with the cell wall 
and cell wall associated proteins (280, 295, 302). Similar to EntV68, the cationic properties of 
LL-37, β-d3, and Hst-5 are thought to promote interactions with the anionic microbial surface 
and the amphipathic structures allow the peptides to interact with microbial membranes (411). 
Thus, I hypothesized that EntV68 may interact with the cell surface of C. albicans in a similar 
fashion. As demonstrated in Figure 5.7, sEntV68 with a C-terminal FITC tag localized to the cell 
surface of C. albicans yeast and hyphal cells, suggesting that the EntV68 mechanism of action 
is cell surface dependent. 
 
EntV68 activity target spectrum 
Since sEntV68 is efficacious in both in vitro and in vivo conditions and has therapeutic 
potential, I tested the efficacy of sEntV68 against clinical isolates of C. albicans and other 
pathogenic Candida species to gain further insight into the spectrum of fungal targets and 
mechanism of action. I found that sEntV68 significantly reduced biofilm formation of clinical 
isolates, including azole resistant strains (Fig. 5.8A) (395, 412). Furthermore, sEntV68 was also 
active against biofilms formed by other C. glabrata, C. tropicalis, and C. parapsilosis (Fig.. 
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Figure 5.6: Deletion of ZCF21 decreased C. albicans sensitivity to E. faecalis supernatant 
and sEntV68.  
C. albicans biofilms grown for 24 hours in YNBAS at 37°C for 24 hours with (A) sterile medium 
(blue) or supernatant (orange) and (B) 0.01% DMSO (blue) or 100 nM sEntV (orange). Biofilm 
biomass was quantified using the resazurin redox assay. Statistically significant differences 
relative to treated and control biofilms were calculated using a Student’s t-test, and are 
indicated by asterisks (**, p<0.007). 
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Figure 5.7: Localization patterns of sEntV68 on the surface of C. albicans.  
Planktonic cultures of C. albicans expressing constitutive mCherry were incubated in YNBAS 
with 100nM sEntV68-FITC at (A) 30°C for hour, (B) 37°C for 1 hour, or (C) 37°C for 1 hour 
without sEntV68-FITC to allow for germ-tube formation followed by 1 hour incubation with 
sEntV68-FITC. Localization of sEntV68-FITC was observed by fluorescence microscopy 
(Olympus IX81) using slidebook 6 (3i, Intelligent Imaging Innovations). (D) Biofilms were grown 
with increasing concentrations of sEntV68 or sEntV68-FITC and the IC50 calculated at 0.3 nM 
and 0.5 nM, respectively.  
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Figure 5.8:. sEntV68 target spectrum.  
(A) sEntV68 inhibitory activity against clinical isolates of C. albicans. Stain names in red are 
resistant clinical isolates that resistant to azoles. C. albicans biofilms grown for 24 hours in 
YNBAS at 37°C for 24 hours with 0.01% DMSO (blue) or 100 nM sEntV (orange). (B) sEntV68 
inhibitory activity against different Candida species. C. albicans, C. tropicalis, C. parapsilosis 
and C. glabrata biofilms grown for 24 hours in RPMI at 37°C for 24 hours with 0.01% DMSO 
(blue) or 100 nM sEntV (orange). Biofilm density was quantified by measuring resazurin 
fluorescence for three separate experiments and statically significant differences were 
calculated using a Student’s t-test (*, p<0.05; **, p<0.01). 
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5.8B). Taken together these results suggest that EntV68 is a specific inhibitor of hyphal and 
biofilm growth with a broad spectrum of activity against C. albicans and Candida spp . 
 
Discussion: 
 The mechanism by which EntV inhibits C. albicans hyphal growth and biofilm formation 
is unresolved. However, homozygous deletion mutants resistant to E. faecalis supernatant 
revealed that hyphal morphogenesis and surface stress response functions are important for 
the mechanism of action. Localization of the fluorescent peptide suggests a cell surface (wall or 
membrane) localization, and I have no evidence that it exerts any cytotoxic or lytic stress 
against C. albicans. Quite the contrary: while sub-nanomolar concentrations of EntV are 
sufficient to inhibit biofilms, concentrations 10,000-fold higher do not reduce fungal growth, 
even in the presence of concurrent stresses that damage the cell wall or membrane.  
 Plausible mechanisms include EntV interfering with a cell surface receptor or a hyphal 
inducing factor or blocking cell-cell or cell-substrate binding mediated by one or more of the C. 
albicans adhesins. Several of the homozygous deletion mutants, including ZCF21, disrupt the 
cell wall composition that could lead to masking of a binding target protein or component of the 
cell wall or membrane. Disruption of the cell wall composition and structure can also impair 
biofilm development and is often mediated by cell stress response (20). Genetic and 
biochemical studies will be necessary to elucidate the mechanism of action.  
 Biofilms provide protection to microbes by production of the ECM that encases the 
microbes protecting them from the immune response and antibiotics (39). Thus, biofilm related 
infections present many clinical challenges by complicating treatment strategies (80). With the 
limited antifungals available fungal infections are difficult to treat. Furthermore, resistance to 
traditional antifungals is an increasing concern. Traditional antifungals interfere with essential 
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biological processes to kill or inhibit fungal growth and can have off target effects that can be 
toxic to the patient (91, 413). To overcome these challenges targeting virulence traits rather 
than essential fungal processes has recently been proposed to alleviate the selection pressure 
for resistance (410).  
 Moreover, targeting virulence factors will keep opportunistic pathogens in check rather 
than disrupting the entire mycoflora with antifungal treatment. One of the most abundant fungal 
species found in humans, C. albicans does not have any known environmental reservoir (410). 
This suggests that C. albicans has a profound association with humans and has coevolved 
considerably with the human host. Additionally, the majority of healthy individuals are colonized 
with C. albicans as part of the normal GI microflora (414, 415). That said, the beneficial effects 
of C. albicans colonization cannot be excluded, and might provide another rationale for why the 
use of an alternative antifungal could be advantageous. Collectively, our work suggests that 
EntV is a promising alternative therapeutic that targets hyphal morphogenesis and biofilm 
development with a spectrum of activity against clinical isolates and other pathogenic Candida 
spp. 
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Chapter 6:  
 
Discussion and Perspectives  
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Summary: 
 E. faecalis and C. albicans occupy overlapping niches as ubiquitous parts of the 
gastrointestinal and oral microbiome. As opportunistic pathogens these species are also 
amongst the most important and problematic nosocomial pathogens. I have observed 
antagonistic interactions between these two species, where virulence of both microbes is 
attenuated in the C. elegans infection model. Inhibition of C. albicans hyphal morphogenesis 
was a striking phenotype observed in this infection model. Inhibition of hyphal morphogenesis 
was also obtained by addition of E. faecalis spent supernatant in the C. elegans infection model 
and in vitro biofilm model (115). 
 I have identified the inhibitory factor as an E. faecalis bacteriocin, EntV, which was 
necessary and sufficient for the reduction of C. albicans virulence and biofilm formation via its 
inhibition of hyphal morphogenesis. As illustrated in Figure 6.1, I have demonstrated that the 
EntV propeptide is post-translational modified for maximum activity. The synthetic version of 
the mature 68-amino acid peptide inhibited biofilm development in multiple media conditions 
and disrupted pre-formed biofilms. sEntV68 was protective in different fungal infection models at 
nanomolar or lower concentrations.   
 First, nematodes treated with the peptide at 0.1 nM are completely resistant to killing by 
C. albicans (data not shown see (303)).  sEntV68 was protective in the macrophage infection 
model and works in synergy with the macrophages increasing their antifungal activity. Finally, 
EntV68 reduced epithelial invasion, inflammation, and fungal burden in a murine model of 
oropharyngeal candidiasis. Hyphal morphogenesis was inhibited in all three models. However, 
EntV68 had no effect on C. albicans viability, even in the presence of significant host-mimicking 
stresses. These findings demonstrate the therapeutic potential of EntV as a novel antifungal 
agent that targets virulence rather than viability, which is important considering the increase in 
resistance to traditional antifungals. 
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Figure 6.1: Summary of EntV processing and activity.  
The inhibitory activity produced by E. faecalis was first characterized using an in vitro biofilm. 
EntV was identified as the inhibitory factor produced by E. faecalis and is proteolytically 
cleaved produce the active peptide that inhibits morphogenesis in the biofilm assay, murine 
macrophage infection model, and murine OPC model. Inhibition of hyphal morphogenesis 
reduced biofilm formation, and attenuated virulence of C. albicans during infection.  
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Furthermore, I demonstrated the physiochemical properties of EntV and the post-translational 
modifications that are necessary for activity. Upon assessment of the other closely related 
class IIIb bacteriocins from different bacteria, I observed prominent similarities in possible post-
translational modifications and predicted secondary structures. This preliminary 
characterization of the class IIIb bacteriocins provides useful insight for the future design of 
EntV-based therapeutic strategies and demonstrates the importance of the class IIIb 
bacteriocins for these Gram-positive bacteria and their conceivable role in fungal-bacterial 
interactions.  
 To understand how E. faecalis inhibits C. albicans biofilms and hyphal morphogenesis, I 
identified C. albicans genes that confer decreased sensitivity to E. faecalis inhibitory activity 
during biofilm development. Screens of homozygous deletion mutants revealed that deletion of 
genes involved in regulation of hyphal morphogenesis, cell wall stress, and cell wall 
architecture decreased sensitivity to E. faecalis supernatant. This suggests that EntV may 
target processes involved in these functions, since perturbation decreases efficacy of E. 
faecalis inhibitory activity. Furthermore, sEntV68 localized to the cell surface of both yeast and 
hyphal cells. As illustrated in Figure 6.2, I have demonstrated that modification of C. albicans 
cell wall components or hyperfilamentation produces decreased sensitivity to E. faecalis 
mediated inhibition of biofilm development. Thus, I hypothesize that EntV targets the cell 
surface, which disrupts cell surface function(s) that are necessary for hyphal morphogenesis 
and biofilm development, most likely a function that is linked between these important virulence 
determinants. I also examined the target spectrum of sEntV68 and found that clinical isolates of 
C. albicans, including azole restraint strains, and other pathogenic Candida spp. are sensitive 
to sEntV68. This suggests that the mechanism of action targets a common function amongst 
these different strains and species. In total, these data demonstrate the therapeutic potential of 
sEntV68 or similar compounds for development of therapeutic strategies that target hyphal 
morphogenesis and biofilm development. 
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Figure 6.2: Summary of homozygous deletion mutant functions.  
Of the 263 mutant screened 39 were less sensitive to E. faecalis supernatant. Collectively, 
most of these mutants have functions associated with cell wall composition and/or hyphal 
morphogenesis. Many of the cell wall mutants have functions associated with cell wall stress 
and are important for maintenance of cell wall integrity and architecture and deletion of these 
genes leads to cell surface remodeling. Of the 24 transcription factors, many have functions 
associated with regulating hyphal morphogenesis and many were hyperfilamentous as result of 
upregulation of hyphal specific genes.   
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C. albicans-E. faecalis interactions during commensalism and pathogenesis 
 Given the epidemiology of E. faecalis and C. albicans infections, their overlapping 
niches, and our current findings, it is plausible that these species have synergism during 
commensal colonization. As I observed previously in the nematode infection model, virulence 
of both microbes was attenuated, suggesting that their interactions promote non-pathogenic 
association with the host (115). Previous studies also demonstrate synergism during 
commensal colonization. Mason et al. (416) demonstrated that E. faecalis becomes more 
abundant after antibiotic treatment in mice colonized with C. albicans in both the stomach and 
the cecum. Considering C. albicans does not naturally colonize the GI tract of mice and 
antibiotic treatment is necessary to establish C. albicans colonization (417); it is plausible that 
the increase in E. faecalis also promotes commensal colonization of C. albicans (418).  
 On the other hand, during infection C. albicans and E. faecalis are commonly co-
isolated in a variety of different types and severity of infections (109, 157, 159, 182). One 
common theme among these co-infections is the status of the host changes due to immune 
dysfunction and/or disruption of anatomical barriers, suggesting that a complex relation exists 
between E. faecalis and C. albicans that is dependent on the host. Consistent with clinical 
reports, Carlson et al. (151) found that co-infection with E. faecalis and C. albicans enhanced 
dissemination of E. faecalis pathogenesis in a murine intraperitoneal infection model. 
Considering these results and the clinical indices of E. faecalis and C. albicans co-infections, it 
is plausible that when immune dysfunction, loss of anatomical barriers, and/or disruption of the 
microflora occurs E. faecalis is able to hitch a ride, so to speak, with C. albicans during 
disseminated infection. A similar occurrence has been demonstrated in C. albicans and P. 
aeruginosa, where in vitro antagonism is observed and clinical co-infections are more severe 
(Chapter 1). 
   In view of our results, current literature, and clinical reports, Figure 6.3 illustrates our 
predicted model of the complex relationship that exists between E. faecalis and C. albicans. In 
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the presence of a healthy host both microbes are able to colonize as commensal microflora. 
However, with a change in the host status both microbes can become pathogenic (8, 366). 
During antibiotic treatment, E. faecalis is capable of surviving because of their genomic 
plasticity and ability to take up resistance genes and virulence traits via conjugation [436]. 
Thus, E. faecalis is capable of surviving with antibiotic treatment along with C. albicans. 
However, with antibiotic treatment the population of E. faecalis is likely reduced, repressing Fsr 
and in turn EntV production (356). Under these conditions, C. albicans is able to grow, 
proliferate, and form hyphae. If the host has a compromised immune response, C. albicans is 
able to disseminate and survive and possibly allow the remaining E. faecalis a mode of 
dissemination (8). In the case of disrupted anatomical barriers, such as seen in intraperitoneal 
infections, both E. faecalis and C. albicans are able to survive in the hostile environment of the 
intraperitoneal cavity allowing further dissemination of both microbes (183, 184). To 
substantiate this model many more questions must be addressed, which will be discussed 
subsequently. 
 
Role of E. faecalis bacteriocins in the host environment 
 Many of the bacteriocins produced by E. faecalis are found on plasmids and vary from 
strain to strain. Different bacteriocins-producing E. faecalis strains have been isolated from a 
broad range of sources, from commensal strains found in food and feces to pathogenic strains 
found in different types of infections. Interestingly, some bacteriocins produced by E. faecium 
are also produced by E. faecalis commensal and pathogenic strains (419). Although the 
majority of bacteriocins produced by E. faecalis target closely related Gram-positive bacteria 
and are thought to be important for competition with other bacteria, cytolysin is the exception 
because it targets other bacteria and eukaryotic cells. Cytolysin production was first observed 
in clinical isolates and conferred increased hemolysis (420). Furthermore, many E. faecalis 
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strains produce multiple bacteriocins and many of the same bacteriocins are produced in 
strains isolated from extremely different environments, indicating that these bacteriocins are not  
  
 
 
Figure 6.3: Model of C. albicans-E. Faecalis interactions in the GI tract.  
In the healthy host C. albicans and E. faecalis have commensal like association with the host. 
There are abundant populations of E. faecalis. Thus, the Fsr system has been stimulated by 
accumulation of the QS molecule GABP and active EntV is being produced in sufficient 
concentrations to inhibit hyphal morphogenesis. In the unhealthy host who has compromised 
immune function, disrupted microflora, and/or loss of anatomical barriers C. albicans is able to 
penetrate the epithelial layer allowing E. faecalis to escape the intestinal lumen. As the status 
of the host deteriorates both C. albicans and E. faecalis become opportunistic pathogens. 
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niche specific and rather have a general advantage in any niche [440].  
 
 
Role of EntV in the host environment 
 EntV is found in all sequenced E. faecalis strains, indicating that entV function is 
important for E. faecalis survival and is not niche specific. As mentioned previously, entV is 
regulated by the Fsr two-component system. The Fsr system is regulated by accumulation of 
the QS molecule GABP, suggesting that production and function of EntV is important when E. 
faecalis populations are at higher concentrations. In an environment such as the human GI 
tract E. faecalis populations can be 107 CFU/μg. In this environment, competition with 
neighboring bacterial species that are closely related and likely require similar nutrients is 
important [441]. Production of a bacteriocin such as EntV could be advantageous.  
 Moreover, production of EntV in the GI tract could also be beneficial during commensal 
colonization with C. albicans. As demonstrated in our current and previous findings, EntV 
promotes commensal-like association with the host in C. albicans by inhibition of hyphal 
morphogenesis (115, 303). Although hyphal cells are considered the invasive and more 
pathogenic form of C. albicans, there is much debate on this topic (47). Some literature 
suggests that the yeast form is the commensal, noninvasive morphology and the hyphal form is 
the invasive pathogenic morphology. This is an over simplification. During invasive infection 
both morphologies are necessary and the dominance of one morphology over the other 
depends on the infected organ (421). Moreover, it is unclear what morphology predominates 
during commensal colonization. Kumamoto et al. (422, 423), reported the expression of hyphal-
associated genes during commensal colonization in a murine GI colonization model, despite 
the fact that C. albicans was found predominately in the yeast form. That said, C. albicans 
mutant strains locked in either the yeast form or hyphal form have attenuated virulence, 
suggesting the transition between the two states is dynamic and necessary for maximum 
virulence (361, 424, 425). Thus, it is plausible that production of EntV during commensal 
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colonization with C. albicans is capable of inhibiting hyphal morphogenesis and promoting 
commensalism. Furthermore, yeast cells are far less immunogenic and are not recognized by 
phagocytes, while hyphal cell are much more immunostimulatory (426-428). Thus, controlling 
hyphal morphogenesis could benefit the microflora including E. faecalis by keeping the immune 
response restrained. 
 The class IIIb bacteriocins, including EntV, are unusual compared to other classes of 
bacteriocins. The majority of propeptides are small where as the class IIIb bacteriocins are 
large and only about half of the propeptide is necessary for activity (Chapter 4). Most 
bacteriocins have an immunity protein that is encoded on a neighboring gene or with the same 
operon. This is the case with the class IIIb bacteriocins, except for EntV where the immunity 
protein has not been identified. Dundar et al. (245) attempted to identify the immunity protein to 
no avail. A translationally coupled gene was identified by bioinformatics as a candidate 
immunity factor (ef1097b). However, deletion of ef1097b had no effect on E. faecalis sensitivity 
to EntV. I considered whether the N-terminal portion of the propeptide might be the immunity 
factor. Nevertheless, ΔentV is not sensitive to sEntV68 (data not shown), suggesting that 
intrinsic immunity to sEntV68 occurs by another mechanism or gene and remains to be 
elucidated.  
 Gene expression data demonstrated that entV expression is the same in the pathogenic 
strain E. faecalis V583 as the commensal strain E. faecalis OG1RF, suggesting that EntV is 
expressed in all E. faecalis strains in a similar manner (356, 357). Furthermore, Bourgogne et 
al. (356), identified a FsrA binding consensus sequence that is present in all strains of 
sequenced E. faecalis. In addition to the Fsr operons, gelE and sprE, and entV, ef1352 that 
encodes a putative magnesium-translocating P-type ATPase was unregulated in response to 
GABP stimulation (Fsr activation) (357). Nonetheless, ef1352 does not have an FsrA binding 
consensus sequence, suggesting that ef1352 is not directly regulated by the Fsr system and 
perhaps is induced by EntV causing ion leakage. This remains to be elucidated and would be in 
stark contrast to the immunity factors of other class IIIb bacteriocins (243, 358, 429).  
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 The EntV mechanism of action against bacteria has not been fully elucidated, aside 
from the non-lytic manner of bactericidal activity. However, other class IIIb bacteriocins have 
been studied in much more detail. DysA (dysgalacticin) is produced by Streptococcus 
dysgalactiae subsp. equisimilis and the mechanism of action for DysA has been investigated in 
some detail. Swe et al. (394, 429) found that DysA has a non-lytic mode of action that is 
bactericidal, inhibited glucose fermentation by targeting glucose/mannose-PTS, increased 
membrane permeability that mediated intracellular ion leakage. Given the similarity in 
secondary structure I hypothesis that EntV has a similar mode of action that is mediated by 
insertion into the membrane of target bacteria (Fig 6.4). AMPs with similar physiochemical 
properties as EntV can target both fungi and bacteria (295, 302, 430). Thus, it is conceivable 
that EntV also interacts with the membrane of C. albicans, albeit to a lesser degree given the 
complex structure of the cell wall of C. albicans and differences in lipid composition compared 
to bacteria (13, 431). Human AMPs that are active against C. albicans, Hst-5, LL-37, hBD-3, 
are also active against bacteria, and inhibit hyphal morphogenesis and biofilm adhesion at sub-
lethal concentrations in C. albicans. Considering this it is plausible that only low concentrations 
of EntV are able to insert into the membrane of C. albicans causing membrane stress that 
mediates inhibition of hyphal morphogenesis and biofilm development. However, given the lack 
of synergism of EntV with known membrane and cell wall stressors, this may be an over 
simplification of a very complex interaction.  
 
Therapeutic potential of bacteriocins and future application 
As previously mentioned, application of bacteriocins as therapeutics for human use has been 
limited to probiotics and application in food as preservatives (Introduction). Reports of in vivo 
use of bacteriocins have also focused on the use of probiotic bacteria that express and 
potentially secrete the bacteriocins in the gastrointestinal tract (432). Although the use of 
bacteriocin-producing probiotics may be as beneficial as prophylactics, application of purified 
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Figure 6.4: Predicted membrane topology of active EntV.  
The two-amphipathic helices of EntV are predicated to insert into the cytoplasmic membrane of 
susceptible targets. The disulfide bridge is predicted to remain on the outer leaflet of the 
membrane. Membrane topology was predicted using PHDhtm transmembrane helices 
predictions (NPS), where the EntV amino acid sequence is compared and aligned to similar 
sequences to obtain a more accurate predicted membrane topology (310). 
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bacteriocins would be superior at countering established infections. Application of purified nisin 
has been successful, but has been limited to application in food (244). One of the greatest 
impediments in the therapeutic application of purified bacteriocins is the stability of the 
bacteriocin in the host environment (433). Engineering bacteriocins to increase stability and 
potency will overcome this problem. To design bacteriocins with increased stability and potency 
an understanding of bacteriocins that are effective in vivo is necessary. The stability and target 
spectrum of EntV have not been extensively studied, thus in the event that an enhanced 
version would be ideal strategies for modification of class II bacteriocins can be used for EntV. 
Another, important factor to consider is that the size of EntV is twice as large as the class II 
bacteriocins, which have been extensively used and tested and are more cost effective 
treatment strategies.  
 The class IIa bacteriocins structure-function relationship has been extensively studied 
and the in vivo efficacy has been examined. Dabour et al. (434) found that intra-gastric 
application of pediocin PA-1, produced by Pediococcus acidilactici, was efficacious in mice with 
GI infections of Listeria monocytogenes. Infected mice where given repeat doses (250 μg/ day) 
of purified pediocin PA-1 for three days, which resulted in up to 2-log reductions in L. 
monocytogenes in feces and translocation into the liver and spleen was slowed. Furthermore, 
L. monocytogenes completely disappeared in the liver and spleen within six days of treatment. 
Another class IIa bacteriocins that has been studied in vivo is piscicolin 126 from 
Carnobacterium piscicola. Ingham et al. (435) found that after tail vein injection into mice 
piscicolin 126 retain activity against L. monocytogenes. Mice were infected intravenously with 
L. monocytogenes followed by intravenous treatment with purified piscicolin 126, which 
significantly reduced L. monocytogenes in the liver and spleen reducing clinical signs of 
disease. Likewise, Rihakova et al. (436) demonstrated that the divercin RV41 bacteriocin 
produced by Carnobacterium divergens significantly reduced L. monocytogenes during 
invasive infection. The efficacy of structural variants with mutation in different amino acids was 
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also tested and while all retained activity against L. monocytogenes the level of potency varied, 
demonstrating that certain amino acids are required for activity.  
 Unlike traditional antibiotics bacteriocins are confronted with challenges related to their 
structure as peptides. The structure-function relationships and in vivo efficacy observations can 
provide insight to determine engineering methods to enhance stability and potency of 
bacteriocins, such as EntV. Some commonly used methods to increase stability are: (1) 
introduction of additional disulfide bridges (437, 438), (2) amino acid substitutions including 
incorporation of D-amino acids (439, 440) (3) encapsulation of bacteriocins in liposomes (441-
443). The class IIa bacteriocins have one or more disulfide bridges that are important for 
activity and target specificity (242). Fimland et al. (437) found that addition of a C-terminal 
disulfide bridge into sakacin P produced by Lactobacillus sakei, which only has an N-terminal 
disulfide bridge, broadened the target spectrum, increased potency and decreased temperature 
sensitivity. To reduce proteolytic cleavage of bacteriocins by proteases found in the 
gastrointestinal tract, O’Shea et al. (439) altered trypsin recognition sites in salivaricin P, a 
class IIb bacteriocin produced by Lactobacillus salivarius. Antimicrobial activity was retained 
with these alterations and salivaricin P variants were resistant to trypsin digestion. In the event 
that modification of the bacteriocin disrupts activity, encapsulation of the bacteriocin can be 
preserving. Were et al. (443) observed that encapsulation of nisin and lysozyme increased 
efficacy of nisin against L. monocytogenes by stabilizing the bacteriocin activity and structure. 
 To enhance the potency of bacteriocins the physiochemical properties that contribute to 
the mode of action must be considered. As demonstrated in Chapter 4, active EntV is 
amphipathic and has a net positive charge (~9.84). Proteolytic cleavage of the propeptide 
increased activity against C. albicans (Chapter 3). This corresponds with enhancement of the 
positive net charge that promotes the initial electrostatic interaction with the target cell. 
Likewise, Kazazic et al. (444) demonstrated that addition of positively charged amino acids at 
specific residues enhanced activity of sakacin P by increasing cell binding.  
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 There are different methods that have been used previously with success to develop 
engineered bacteriocins (433). Rational substitution of amino acids is one such method that 
depends on the structure-function relationship of the bacteriocins. Use of error-prone PCR to 
randomly generate mutants is another approach. However, greater modifications are usually 
required to improve bacteriocin activity, as bacteriocins have evolved to be as effective as 
possible (242, 445). An alternative approach that allows for major modification is creating 
chimeras of with different bacteriocins from the same class to create a DNA-shuffling library to 
create hybrids with increased activity and broadened spectrum targets (445).  
 Traditional antimicrobial therapies often have broader-spectrum of activity than 
bacteriocins, thus having a greater impact on the commensal microflora. Often keeping 
opportunistic pathogens at bay, the commensal microflora acts a barrier to infection and 
disruption of the commensal microflora with antimicrobial treatment is a growing concern. An 
advantage over traditional antimicrobials, bacteriocins often have specific microbial targets, and 
due to their composition are less likely to be toxic because they are easily broken down into 
nontoxic amino acids. Correspondingly, our cytotoxicity assays (Chapter 3) demonstrated that 
sEntV68 is not toxic to murine macrophages or Human cervical epithelial cells. Likewise, 
Jasniewski et al. (446) found that two class IIa bacteriocins, Cbn BM1 and Cbn B2 produced by 
Carnobacterium maltaromaticum, in combination or alone had no cytotoxic effects on human 
gastrointestinal cells (Caco-2) at concentration 100-folder than what was required for 
antimicrobial activity. 
 
Future perspectives and directions 
 As mentioned previously, C. albicans biofilms are a growing concern in the clinical 
setting. Due to their complex structure, encasement in the ECM, and production of persister 
cells traditional antifungals are ineffective at eradicating C. albicans biofilms. In addition there 
are currently no biofilm-specific therapeutics used clinically further complicating treatment 
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strategies (39). Several chemicals have been identified that specifically target biofilm formation, 
while others target hyphal morphogenesis (92, 111, 447). These studies are insightful and 
show promise for the development of biofilm specific treatment strategies. Likewise, our 
findings demonstrate the possible use of a natural-based peptide for control and treatment of 
C. albicans biofilms that has many advantages over the use of other treatment. 
 Here, I have described very complex and ecologically important interactions between E. 
faecalis and C. albicans. As described in Chapter 3, I have identified a bacteriocin, EntV that 
has therapeutic potential in different in vitro and in vivo models. Furthermore, I have 
characterized EntV activity with respect to post-translational processing that results in 
production of a highly active version of EntV. Additionally, I have identified genes that when 
deleted decrease C. albicans sensitivity to E. faecalis supernatant and sEntV68. Lastly, I 
examined the spectrum of target activity for sEntV68. Although, I have addressed many of the 
questions I had when starting this project, there are still many more intriguing questions left to 
answer. 
 
Is sEntV68 efficacious in other mammalian infection models with C. albicans? 
 C. albicans can cause a variety of different infectious, from superficial infections (OPC, 
vaginal candidiasis) to systemic infections (endocarditis, candidemia, intraperitoneal infections). 
Recall that during invasive infection the yeast-hyphal transition is necessary for maximum 
virulence. However, the dominance of one morphology over the other depends on the infected 
organ (421). Thus, it would be insightful to assess the efficacy of EntV an invasive infection 
model, such as the intravenous tail vein injection model. Considering that other bacteriocins are 
effective in invasive bacterial infections, EntV would be expected to decrease dissemination of 
C. albicans. Nevertheless, EntV does not have fungicidal activity during planktonic growth so 
the effects of EntV may be moderate. 
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  Given our observation in the C. elegans infection model, where commensal-like 
association with C. elegans was observed, I speculate that these species have synergism 
during commensal colonization. This could be confirmed using the murine colonization model 
(422). Perez et al. (9) screened homozygous transcription factor deletion mutants in both the 
murine intestinal colonization and systemic infection models. Eight transcriptional regulators 
were identified that have roles in at least one of the models examined. 800 target genes where 
identified by genome-wide chromatin immunoprecipitation that are regulated by the eight 
transcriptional regulators. Interestingly, many pathogenesis associated genes were upregulated 
during commensal colonization suggesting that commensalism and pathogenicity are 
genetically intertwined 
Addition of EntV to either of these models could change the gene expression profiles or the 
specific genes identified. 
 
Is sEntV68 efficacious against other fungal pathogenes not closely related to C. 
albicans? 
 sEntV68 was active against biofilms formed by other C. glabrata, C. tropicalis, and C. 
parapsilosis. Although all of these species belong to the Candida genus, only C. tropicalis and 
C. parapsilosisi are closely related to C. albicans and are part of the CUG clade that translate 
the CUG codon as serine instead of leucine (448). C. glabrata is more closely related to S. 
cerevisiae. The Candida genus originally included yeast species that are able to form hyphae 
or psuedohyphae and have no observed sexual spores. Although C. albicans remains the 
leading of cause of candidiasis, isolation of non-albicans Candida (NAC) species is increasing 
in patients. C. glabrata  followed by C. parapsilosis and C. tropicalis were the most common 
NAC species isolated worldwide in a 10 year retrospective analysis of NAC species infections 
(449). Interestingly, EntV has inhibitory activity against all of these species, suggesting the 
mechanism of action requires a common feature found in these different species. 
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 C. albicans, Cryptococcus neoformans and Aspergillus fumigatus are among the most 
prevalent fungal pathogens. Resistance to traditional antifungals is also an increasing problem 
in C. neoformans and A. fumigatus infections (450). Thus, development of novel treatment 
strategies that do not promote resistance is also critical to treating these infections. Since C. 
neoformans and A. fumigatus are important pathogens and not closely related to C. albicans, 
examining the efficacy of EntV would provide useful insight into the mechanism of action and 
could be used as a novel treatment strategy.   
 
What is the role of the disulfide bridge and how is it formed? 
 Recall that EntV contains two cysteines that form a putative disulfide bond that is 
necessary for bactericidal activity and inhibitory activity against C. albicans (Chapter 4)  (358). 
Until recently disulfide bond formation in Gram-positive bacteria was not well understood and 
was not thought be important (381). However, recently thiol-disulfide oxidoreductases (DsbA-
like proteins) have been characterized in Gram-positive actinobacteria (382). Furthermore, a 
homolog of dsbA has been identified in E. faecalis and disruption of dsbA by transposon 
mutagenesis resulted in reduced inhibitory activity suggesting that dsbA is required for 
producing active EntV68. However, the role of the disulfide bond formation by DsbA remains to 
be fully elucidated. I are currently examining the role of dsbA in producing active EntV68 and 
other possible roles in E. faecalis (Armand Brown, Ph.D.). Currently, there are only limited 
reports on the dsbA homolog (EF1088) in E. faecalis thus this work will not only add to our 
understand of EntV, but the physiology of E. faecalis. 
 
What role if any does SprE play in post-translational processing of sEntV68? 
 I hypothesized that GelE and/or SprE proteolytically process EntV. However, I did not 
determine the role of SprE for EntV68 activity. To address this, we are currently working on 
examining the in vitro processing of EntV in deletion mutant of E. faecalis (ΔgelE, ΔsprE, 
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ΔgelEΔsprE) compared to WT. EntV will be purified from the supernatant and cell lysates of the 
E. faecalis strains and subjected to SDS-PAGE and visualized by Istern blotting polyclonal 
antibodies. Our previous attempts to observe in vivo cleavage of EntV did not work because we 
was expressing EntV with a C-terminal Hexa-HIS tag expressed from the endogenous 
promoter in the mutant strains and WT E. faecalis. However, I was not able to visualize the 
EntV-6XHIS by western blot with HIS antibodies. The EntV-6XHIS construct fully 
complemented the ΔentV mutant, suggesting EntV is being produced. This along with our in 
silico analysis of proteolytic cleavage by the GelE homolog, thermolysin, suggests that the 
Hexa-HIS tag is being cleaved in vivo by GelE. 
 
What is the sEntV68 mode of action against C. albicans? 
 As previously mentioned, I speculate that EntV interacts with the membrane of C. 
albicans at low concentration causing minimal perturbation of the membrane that in turn 
disrupts biofilm formation and hyphal morphogenesis. This hypothesis also corresponds with 
our mutant library screens, where deletion of genes that disrupt the cell wall components or 
increase filamentation are less sensitive to E. faecalis supernatant. Thus, it is plausible that 
disruption of the cell wall components masks or interferes with EntV targeting the membrane. If 
indeed EntV68 is causing membrane stress by leakage of ions then there should be a change in 
membrane potential and intracellular ATP, which can be measured and quantified using 
fluorescence assays and bioluminescence assays, respectively (382).   
 Furthermore, treatment of C. albicans with human AMPs LL-37, β-defensin-3 hβD-3, or 
Hst-5 causes vacuolar expansion, which is thought to occur as a result of osmotic stress from 
membrane permeabilization and cytosolic ion leakage (280, 451). The vacuole can be 
visualized by staining with FM4-64 (Invitrogen), a red fluorescent lipophilic stain that 
intercalates into the membrane and then is transported to the vacuole, allowing assessment of 
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the physical characteristics of the vacuole (302, 452). This could determine if E. faecalis 
causes membrane perturbation resulting in an increase in vacuole size.  
 
Are the other class IIIb bacteriocins active against C. albicans? 
 Examining the efficacy of the other class IIIb bacteriocins against C. albicans could 
provide further insight into the mechanism of action and would also suggest that the 
interactions observed between E. faecalis and C. albicans are more widespread, which has 
ecological implications. Furthermore, understanding the structure differences and possible 
activity differences could contribute to engineering possibilities of EntV68 (51, 453). As 
mentioned previously, the potency and stability can be improved by enhancing the 
physiochemical properties that contribute to the mode of action. If these bacteriocins are active 
against C. albicans the construction of chimeric bacteriocins is possible using different portion 
of the class IIIb bacteriocins to create hybrids that may have increased activity and broadened 
target spectrums (433). This could also provide insight into what portions of the peptides are 
necessary for activity increasing our ability to develop EntV-based treatment strategies.  
 
How does C. albicans gene expression change in the presence of E. faecalis?  
 The EntV mechanism of action is one of the most important questions left to answer. 
Changes in C. albicans gene expression in the presence of E. faecalis, E. faecalis supernatant, 
and EntV68 can be used to elucidate the mechanism of action. The most comprehensive way to 
address this question would be by RNA sequencing, which would tell us the global changes in 
gene expression. This assay can be done in C. albicans grown in the in vitro biofilm assay 
grown in YNBAS for 24 hours. Previous studies have observed gene expression changes in C. 
albicans grown as monoculture and polymicrobial biofilms with different bacteria and growth 
conditions (445). While the transcription factor mutant library screen gives some insight into 
gene regulation in the presence E. faecalis supernatant only a select number of genes can be 
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assessed, which only include non-essential genes and only a small portion of the genes 
expressed by C. albicans. RNA sequencing can also provide insight into gene expression in 
different infection models that have already been tested (nematode, macrophage, OPC) or new 
models to understand the effects of EntV during colonization and systemic infections. Not only 
will RNA sequencing provide insight into gene expression of C. albicans, but also gene 
expression of E. faecalis.  
 I also observed attenuation of E. faecalis virulence in the C. elegans infection model, 
where survival of the nematode was increased during co-infection with C. albicans and E. 
faecalis compared to nematodes infected with E. faecalis only. The E. faecalis mode of 
virulence is less striking than that of C. albicans, where hyphal cells invade through the body of 
the nematode. Nematodes infected with E. faecalis become impacted with the bacteria and are 
unable to expel them and eventually die (LD~10). Preliminary observation demonstrate that 
spent media from C. albicans-E. faecalis biofilms inhibits biofilm formation of E. faecalis 
(Melissa Cruz). Furthermore, alteration of bacterial gene expression by C. albicans has been 
previously reported, such as what is seen in S. aureus and C. albicans biofilms (42, 454, 455).  
 This project has overall provided valuable insight into the growing knowledge of 
polymicrobial interactions. Moreover, I have demonstrated that a bacteriocin produced by E. 
faecalis has therapeutic potential against C. albicans in different in vitro and in vivo assays. The 
future directions of this study can lead to advancements in treatment of antifungal resistant C. 
albicans by exploiting bacterial mediated mechanisms to treat C. albicans infections.  
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